{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T05:34:06Z","timestamp":1773293646147,"version":"3.50.1"},"reference-count":203,"publisher":"The Pediatric Pharmacy Association","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"abstract":"<jats:p>Naltrexone (NTX) is a well-tolerated drug with a wide safety margin and mechanism of action that affords use across a wide variety of indications in adults and children. By antagonizing the opioid reward system, NTX can modulate behaviors that involve compulsivity or impulsivity, such as substance use, obesity, and eating disorders. Evidence regarding the disposition and efficacy of NTX is mainly derived from adult studies of substance use disorders and considerable variability exists. Developmental changes, plausible disease-specific alterations and genetic polymorphisms in NTX disposition, and pharmacodynamic pathways should be taken into consideration when optimizing the use of NTX in the pediatric population. This review highlights the current state of the evidence and gaps in knowledge regarding NTX to facilitate evidence-based pharmacotherapy of mental health conditions, for which few pharmacologic options exist.<\/jats:p>","DOI":"10.5863\/1551-6776-26.7.675","type":"journal-article","created":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T21:00:02Z","timestamp":1632517202000},"page":"675-695","source":"Crossref","is-referenced-by-count":7,"title":["Developmental Considerations for the Use of Naltrexone in Children and Adolescents"],"prefix":"10.5863","volume":"26","author":[{"given":"Stephani L.","family":"Stancil","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Abdel-Rahman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jon","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3883","reference":[{"key":"i1551-6776-26-7-675-b1","article-title":"Naltrexone Revia [package insert]","year":"2013","unstructured":"Naltrexone Revia [package insert].\n\t\t\t\t\tPomona, NY:\n\t\t\t\t\tBarr Pharmaceuticals Inc;\n\t\t\t\t\t2013.\n\t\t\t\t\tAccessed September 17, 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/018932s017lbl.pdf"},{"issue":"8","key":"i1551-6776-26-7-675-b2","series-title":"JAMA Pediatr","first-page":"747","article-title":"Trends in receipt of buprenorphine and naltrexone for opioid use disorder among adolescents and young adults, 2001\u20132014","volume":"171","year":"2017","unstructured":"Hadland\n              SE,\n            \n            \n              Wharam\n              JF,\n            \n            \n              Schuster\n              MA,\n            \n          \n          .\n\t\t\t\t\tTrends in receipt of buprenorphine and naltrexone for opioid use disorder among adolescents and young adults, 2001\u20132014.\n\t\t\t\t\tJAMA Pediatr.\n\t\t\t\t\t2017;\n\t\t\t\t\t171(\n\t\t\t\t\t8):\n\t\t\t\t\t747\u2013\n\t\t\t\t\t755."},{"issue":"2","key":"i1551-6776-26-7-675-b3","series-title":"Am J Addict","first-page":"77","article-title":"No increased pain among opioid-dependent individuals treated with extended-release naltrexone or buprenorphine-naloxone: a 3-month randomized study and 9-month open-treatment follow-up study","volume":"28","year":"2019","unstructured":"Latif\n              ZE,\n            \n            \n              Solli\n              KK,\n            \n            \n              Opheim\n              A,\n            \n          \n          .\n\t\t\t\t\tNo increased pain among opioid-dependent individuals treated with extended-release naltrexone or buprenorphine-naloxone: a 3-month randomized study and 9-month open-treatment follow-up study.\n\t\t\t\t\tAm J Addict.\n\t\t\t\t\t2019;\n\t\t\t\t\t28(\n\t\t\t\t\t2):\n\t\t\t\t\t77\u2013\n\t\t\t\t\t85."},{"issue":"10","key":"i1551-6776-26-7-675-b4","series-title":"Curr Psychiatry Rep","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1007\/s11920-013-0396-x","article-title":"Altered brain reward circuits in eating disorders: chicken or egg?","volume":"15","year":"2013","unstructured":"Frank\n              GK.\n            \n          \n          Altered brain reward circuits in eating disorders: chicken or egg?\n          \n            Curr Psychiatry Rep\n          .\n\t\t\t\t\t2013;\n\t\t\t\t\t15(\n\t\t\t\t\t10):\n\t\t\t\t\t396.\n\t\t\t\t\t10.1007\/s11920-013-0396-x"},{"issue":"6","key":"i1551-6776-26-7-675-b5","series-title":"J Psychopharmacol","first-page":"770","article-title":"Dopamine and mu-opioid receptor dysregulation in the brains of binge-eating female rats--possible relevance in the psychopathology and treatment of binge-eating disorder","volume":"31","year":"2017","unstructured":"Heal\n              DJ,\n            \n            \n              Hallam\n              M,\n            \n            \n              Prow\n              M,\n            \n          \n          .\n\t\t\t\t\tDopamine and mu-opioid receptor dysregulation in the brains of binge-eating female rats--possible relevance in the psychopathology and treatment of binge-eating disorder.\n\t\t\t\t\tJ Psychopharmacol.\n\t\t\t\t\t2017;\n\t\t\t\t\t31(\n\t\t\t\t\t6):\n\t\t\t\t\t770\u2013\n\t\t\t\t\t783."},{"issue":"9\u201310","key":"i1551-6776-26-7-675-b6","series-title":"Psychopharmacology (Berl)","first-page":"1439","article-title":"Feeding-modulatory effects of mu-opioids in the medial prefrontal cortex: a review of recent findings and comparison to opioid actions in the nucleus accumbens","volume":"234","year":"2017","unstructured":"Selleck\n              RA,\n            \n            \n              Baldo\n              BA.\n            \n          \n          Feeding-modulatory effects of mu-opioids in the medial prefrontal cortex: a review of recent findings and comparison to opioid actions in the nucleus accumbens.\n\t\t\t\t\tPsychopharmacology (Berl).\n\t\t\t\t\t2017;\n\t\t\t\t\t234(\n\t\t\t\t\t9\u201310):\n\t\t\t\t\t1439\u2013\n\t\t\t\t\t1449."},{"issue":"6","key":"i1551-6776-26-7-675-b7","series-title":"Arch Gen Psychiatry","first-page":"784","article-title":"Naltrexone, an antagonist for the treatment of heroin dependence: effects in man","volume":"28","year":"1973","unstructured":"Martin\n              WR,\n            \n            \n              Jasinski\n              DR,\n            \n            \n              Mansky\n              PA.\n            \n          \n          Naltrexone, an antagonist for the treatment of heroin dependence: effects in man.\n\t\t\t\t\tArch Gen Psychiatry.\n\t\t\t\t\t1973;\n\t\t\t\t\t28(\n\t\t\t\t\t6):\n\t\t\t\t\t784\u2013\n\t\t\t\t\t791."},{"issue":"1","key":"i1551-6776-26-7-675-b8","series-title":"J Med Toxicol","first-page":"71","article-title":"Naltrexone: not just for opioids anymore","volume":"12","year":"2016","unstructured":"Sudakin\n              D.\n            \n          \n          Naltrexone: not just for opioids anymore.\n\t\t\t\t\tJ Med Toxicol.\n\t\t\t\t\t2016;\n\t\t\t\t\t12(\n\t\t\t\t\t1):\n\t\t\t\t\t71\u2013\n\t\t\t\t\t75."},{"issue":"7","key":"i1551-6776-26-7-675-b9","series-title":"Drug Metab Dispos","first-page":"690","article-title":"Pharmacokinetic interaction between naloxone and naltrexone following intranasal administration to healthy subjects","volume":"47","year":"2019","unstructured":"Krieter\n              P,\n            \n            \n              Chiang\n              CN,\n            \n            \n              Gyaw\n              S,\n            \n          \n          .\n\t\t\t\t\tPharmacokinetic interaction between naloxone and naltrexone following intranasal administration to healthy subjects.\n\t\t\t\t\tDrug Metab Dispos.\n\t\t\t\t\t2019;\n\t\t\t\t\t47(\n\t\t\t\t\t7):\n\t\t\t\t\t690\u2013\n\t\t\t\t\t698."},{"issue":"7","key":"i1551-6776-26-7-675-b10","series-title":"J Clin Pharmacol","first-page":"947","article-title":"Enhanced intranasal absorption of naltrexone by dodecyl maltopyranoside: implications for the treatment of opioid overdose","volume":"59","year":"2019","unstructured":"Krieter\n              P,\n            \n            \n              Gyaw\n              S,\n            \n            \n              Chiang\n              CN,\n            \n          \n          .\n\t\t\t\t\tEnhanced intranasal absorption of naltrexone by dodecyl maltopyranoside: implications for the treatment of opioid overdose.\n\t\t\t\t\tJ Clin Pharmacol.\n\t\t\t\t\t2019;\n\t\t\t\t\t59(\n\t\t\t\t\t7):\n\t\t\t\t\t947\u2013\n\t\t\t\t\t957."},{"key":"i1551-6776-26-7-675-b11","series-title":"NIDA Res Monogr","first-page":"147","article-title":"The clinical pharmacology of naltrexone: pharmacology and pharmacodynamics","volume":"28","year":"1981","unstructured":"Verebey\n              K.\n            \n          \n          The clinical pharmacology of naltrexone: pharmacology and pharmacodynamics.\n\t\t\t\t\tNIDA Res Monogr.\n\t\t\t\t\t1981;\n\t\t\t\t\t28:\n\t\t\t\t\t147\u2013\n\t\t\t\t\t158."},{"issue":"3","key":"i1551-6776-26-7-675-b12","series-title":"Diabetes Care","first-page":"847","article-title":"Naltrexone improves blood glucose control in type 1 diabetic women with severe and chronic eating disorders","volume":"27","year":"2004","unstructured":"Raingeard\n              I,\n            \n            \n              Courtet\n              P,\n            \n            \n              Renard\n              E,\n            \n            \n              Bringer\n              J.\n            \n          \n          Naltrexone improves blood glucose control in type 1 diabetic women with severe and chronic eating disorders.\n\t\t\t\t\tDiabetes Care.\n\t\t\t\t\t2004;\n\t\t\t\t\t27(\n\t\t\t\t\t3):\n\t\t\t\t\t847\u2013\n\t\t\t\t\t848."},{"issue":"3","key":"i1551-6776-26-7-675-b13","series-title":"Alcohol Clin Exp Res","first-page":"480","article-title":"Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone","volume":"30","year":"2006","unstructured":"Dunbar\n              JL,\n            \n            \n              Turncliff\n              RZ,\n            \n            \n              Dong\n              Q,\n            \n          \n          .\n\t\t\t\t\tSingle- and multiple-dose pharmacokinetics of long-acting injectable naltrexone.\n\t\t\t\t\tAlcohol Clin Exp Res.\n\t\t\t\t\t2006;\n\t\t\t\t\t30(\n\t\t\t\t\t3):\n\t\t\t\t\t480\u2013\n\t\t\t\t\t490."},{"issue":"1","key":"i1551-6776-26-7-675-b14","series-title":"BMC Med","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12916-018-1242-0","article-title":"Serious adverse events reported in placebo randomised controlled trials of oral naltrexone: a systematic review and meta-analysis","volume":"17","year":"2019","unstructured":"Bolton\n              M,\n            \n            \n              Hodkinson\n              A,\n            \n            \n              Boda\n              S,\n            \n          \n          .\n\t\t\t\t\tSerious adverse events reported in placebo randomised controlled trials of oral naltrexone: a systematic review and meta-analysis.\n\t\t\t\t\tBMC Med.\n\t\t\t\t\t2019;\n\t\t\t\t\t17(\n\t\t\t\t\t1):\n\t\t\t\t\t10.\n\t\t\t\t\t10.1186\/s12916-018-1242-0"},{"issue":"9","key":"i1551-6776-26-7-675-b15","series-title":"J Child Adolesc Psycho-pharmacol","first-page":"721","article-title":"Naltrexone reduces binge eating and purging in adolescents in an eating disorder program","volume":"29","year":"2019","unstructured":"Stancil\n              SL,\n            \n            \n              Adelman\n              W,\n            \n            \n              Dietz\n              A,\n            \n            \n              Abdel-Rahman\n              S.\n            \n          \n          Naltrexone reduces binge eating and purging in adolescents in an eating disorder program.\n\t\t\t\t\tJ Child Adolesc Psycho-pharmacol.\n\t\t\t\t\t2019;\n\t\t\t\t\t29(\n\t\t\t\t\t9):\n\t\t\t\t\t721\u2013\n\t\t\t\t\t724."},{"issue":"3","key":"i1551-6776-26-7-675-b16","series-title":"J Child Adolesc Psycho-pharmacol","first-page":"157","article-title":"Cardiovascular and other physical effects of acute administration of naltrexone in autistic children","volume":"3","year":"1993","unstructured":"Herman\n              BH,\n            \n            \n              Asleson\n              GS,\n            \n            \n              Powell\n              A,\n            \n          \n          .\n\t\t\t\t\tCardiovascular and other physical effects of acute administration of naltrexone in autistic children.\n\t\t\t\t\tJ Child Adolesc Psycho-pharmacol.\n\t\t\t\t\t1993;\n\t\t\t\t\t3(\n\t\t\t\t\t3):\n\t\t\t\t\t157\u2013\n\t\t\t\t\t168."},{"issue":"2","key":"i1551-6776-26-7-675-b17","series-title":"Dev Pharmacol Ther","first-page":"81","article-title":"Role for opioid peptides in self-injurious behavior: dissociation from autonomic nervous system functioning","volume":"12","year":"1989","unstructured":"Herman\n              BH,\n            \n            \n              Hammock\n              MK,\n            \n            \n              Egan\n              J,\n            \n          \n          .\n\t\t\t\t\tRole for opioid peptides in self-injurious behavior: dissociation from autonomic nervous system functioning.\n\t\t\t\t\tDev Pharmacol Ther.\n\t\t\t\t\t1989;\n\t\t\t\t\t12(\n\t\t\t\t\t2):\n\t\t\t\t\t81\u2013\n\t\t\t\t\t89."},{"issue":"2","key":"i1551-6776-26-7-675-b18","series-title":"J Am Acad Child Adolesc Psychiatry","first-page":"200","article-title":"Naltrexone in autistic children: an acute open dose range tolerance trial","volume":"28","year":"1989","unstructured":"Campbell\n              M,\n            \n            \n              Overall\n              JE,\n            \n            \n              Small\n              AM,\n            \n          \n          .\n\t\t\t\t\tNaltrexone in autistic children: an acute open dose range tolerance trial.\n\t\t\t\t\tJ Am Acad Child Adolesc Psychiatry.\n\t\t\t\t\t1989;\n\t\t\t\t\t28(\n\t\t\t\t\t2):\n\t\t\t\t\t200\u2013\n\t\t\t\t\t206."},{"issue":"5","key":"i1551-6776-26-7-675-b19","series-title":"J Child Adolesc Psychopharmacol","first-page":"723","article-title":"Naltrexone treatment of adolescent alcoholics: an open-label pilot study","volume":"15","year":"2005","unstructured":"Deas\n              D,\n            \n            \n              May\n              MP,\n            \n            \n              Randall\n              C,\n            \n          \n          .\n\t\t\t\t\tNaltrexone treatment of adolescent alcoholics: an open-label pilot study.\n\t\t\t\t\tJ Child Adolesc Psychopharmacol.\n\t\t\t\t\t2005;\n\t\t\t\t\t15(\n\t\t\t\t\t5):\n\t\t\t\t\t723\u2013\n\t\t\t\t\t728."},{"issue":"6","key":"i1551-6776-26-7-675-b20","series-title":"Neurosci Biobehav Rev","first-page":"713","article-title":"Opioid peptides and the control of human ingestive behaviour","volume":"26","year":"2002","unstructured":"Yeomans\n              MR,\n            \n            \n              Gray\n              RW.\n            \n          \n          Opioid peptides and the control of human ingestive behaviour.\n\t\t\t\t\tNeurosci Biobehav Rev.\n\t\t\t\t\t2002;\n\t\t\t\t\t26(\n\t\t\t\t\t6):\n\t\t\t\t\t713\u2013\n\t\t\t\t\t728."},{"issue":"2","key":"i1551-6776-26-7-675-b21","series-title":"JAMA Psychiatry","first-page":"127","article-title":"Anxiety, depression, and insomnia among adults with opioid dependence treated with extended-release naltrexone vs buprenorphine-naloxone: a randomized clinical trial and follow-up study","volume":"76","year":"2019","unstructured":"Latif\n              ZE,\n            \n            \n              \u0160altyte Benth\n              J,\n            \n            \n              Solli\n              KK,\n            \n          \n          .\n\t\t\t\t\tAnxiety, depression, and insomnia among adults with opioid dependence treated with extended-release naltrexone vs buprenorphine-naloxone: a randomized clinical trial and follow-up study.\n\t\t\t\t\tJAMA Psychiatry.\n\t\t\t\t\t2019;\n\t\t\t\t\t76(\n\t\t\t\t\t2):\n\t\t\t\t\t127\u2013\n\t\t\t\t\t134."},{"issue":"12","key":"i1551-6776-26-7-675-b22","series-title":"Biol Psychiatry","first-page":"1023","article-title":"The effects of chronic naltrexone treatment in young autistic children: a double-blind placebo-controlled crossover study","volume":"39","year":"1996","unstructured":"Willemsen-Swinkels\n              SH,\n            \n            \n              Buitelaar\n              JK,\n            \n            \n              van Engeland\n              H.\n            \n          \n          The effects of chronic naltrexone treatment in young autistic children: a double-blind placebo-controlled crossover study.\n\t\t\t\t\tBiol Psychiatry.\n\t\t\t\t\t1996;\n\t\t\t\t\t39(\n\t\t\t\t\t12):\n\t\t\t\t\t1023\u2013\n\t\t\t\t\t1031."},{"issue":"5","key":"i1551-6776-26-7-675-b23","series-title":"J Am Acad Child Adolesc Psychiatry","first-page":"587","article-title":"Naltrexone and communication skills in young children with autism","volume":"38","year":"1999","unstructured":"Feldman\n              HM,\n            \n            \n              Kolmen\n              BK,\n            \n            \n              Gonzaga\n              AM.\n            \n          \n          Naltrexone and communication skills in young children with autism.\n\t\t\t\t\tJ Am Acad Child Adolesc Psychiatry.\n\t\t\t\t\t1999;\n\t\t\t\t\t38(\n\t\t\t\t\t5):\n\t\t\t\t\t587\u2013\n\t\t\t\t\t593."},{"issue":"2","key":"i1551-6776-26-7-675-b24","series-title":"J Am Acad Child Adolesc Psychiatry","first-page":"223","article-title":"Naltrexone in young autistic children: a double-blind, placebo-controlled crossover study","volume":"34","year":"1995","unstructured":"Kolmen\n              BK,\n            \n            \n              Feldman\n              HM,\n            \n            \n              Handen\n              BL,\n            \n            \n              Janosky\n              JE.\n            \n          \n          Naltrexone in young autistic children: a double-blind, placebo-controlled crossover study.\n\t\t\t\t\tJ Am Acad Child Adolesc Psychiatry.\n\t\t\t\t\t1995;\n\t\t\t\t\t34(\n\t\t\t\t\t2):\n\t\t\t\t\t223\u2013\n\t\t\t\t\t231."},{"issue":"11","key":"i1551-6776-26-7-675-b25","series-title":"J Am Acad Child Adolesc Psychiatry","first-page":"1570","article-title":"Naltrexone in young autistic children: replication study and learning measures","volume":"36","year":"1997","unstructured":"Kolmen\n              BK,\n            \n            \n              Feldman\n              HM,\n            \n            \n              Handen\n              BL,\n            \n            \n              Janosky\n              JE.\n            \n          \n          Naltrexone in young autistic children: replication study and learning measures.\n\t\t\t\t\tJ Am Acad Child Adolesc Psychiatry.\n\t\t\t\t\t1997;\n\t\t\t\t\t36(\n\t\t\t\t\t11):\n\t\t\t\t\t1570\u2013\n\t\t\t\t\t1578."},{"issue":"3","key":"i1551-6776-26-7-675-b26","series-title":"Pharmacotherapy","first-page":"382","article-title":"The safety and efficacy of low-dose naltrexone in the management of chronic pain and inflammation in multiple sclerosis, fibromyalgia, Crohn's disease, and other chronic pain disorders","volume":"38","year":"2018","unstructured":"Patten\n              DK,\n            \n            \n              Schultz\n              BG,\n            \n            \n              Berlau\n              DJ.\n            \n          \n          The safety and efficacy of low-dose naltrexone in the management of chronic pain and inflammation in multiple sclerosis, fibromyalgia, Crohn's disease, and other chronic pain disorders.\n\t\t\t\t\tPharmacotherapy.\n\t\t\t\t\t2018;\n\t\t\t\t\t38(\n\t\t\t\t\t3):\n\t\t\t\t\t382\u2013\n\t\t\t\t\t389."},{"issue":"3","key":"i1551-6776-26-7-675-b27","series-title":"J Drugs Dermatol","first-page":"235","article-title":"Low dose naltrexone in dermatology","volume":"18","year":"2019","unstructured":"Jaros\n              J,\n            \n            \n              Lio\n              P.\n            \n          \n          Low dose naltrexone in dermatology.\n\t\t\t\t\tJ Drugs Dermatol.\n\t\t\t\t\t2019;\n\t\t\t\t\t18(\n\t\t\t\t\t3):\n\t\t\t\t\t235\u2013\n\t\t\t\t\t238."},{"issue":"2","key":"i1551-6776-26-7-675-b28","series-title":"JAMA Dermatol","first-page":"229","article-title":"Utility of naltrexone treatment for chronic inflammatory dermatologic conditions: a systematic review","volume":"155","year":"2019","unstructured":"Ekelem\n              C,\n            \n            \n              Juhasz\n              M,\n            \n            \n              Khera\n              P,\n            \n            \n              Mesinkovska\n              NA.\n            \n          \n          Utility of naltrexone treatment for chronic inflammatory dermatologic conditions: a systematic review.\n\t\t\t\t\tJAMA Dermatol.\n\t\t\t\t\t2019;\n\t\t\t\t\t155(\n\t\t\t\t\t2):\n\t\t\t\t\t229\u2013\n\t\t\t\t\t236."},{"issue":"1","key":"i1551-6776-26-7-675-b29","series-title":"Eur J Neurosci","first-page":"20","article-title":"Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4)","volume":"28","year":"2008","unstructured":"Hutchinson\n              MR,\n            \n            \n              Zhang\n              Y,\n            \n            \n              Brown\n              K,\n            \n          \n          .\n\t\t\t\t\tNon-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4).\n\t\t\t\t\tEur J Neurosci.\n\t\t\t\t\t2008;\n\t\t\t\t\t28(\n\t\t\t\t\t1):\n\t\t\t\t\t20\u2013\n\t\t\t\t\t29."},{"issue":"5","key":"i1551-6776-26-7-675-b30","series-title":"Br J Pharmacol","first-page":"856","article-title":"Pharmacological characterization of the opioid inactive isomers (+)-naltrexone and (+)-naloxone as antagonists of toll-like receptor 4","volume":"173","year":"2016","unstructured":"Wang\n              X,\n            \n            \n              Zhang\n              Y,\n            \n            \n              Peng\n              Y,\n            \n          \n          .\n\t\t\t\t\tPharmacological characterization of the opioid inactive isomers (+)-naltrexone and (+)-naloxone as antagonists of toll-like receptor 4.\n\t\t\t\t\tBr J Pharmacol.\n\t\t\t\t\t2016;\n\t\t\t\t\t173(\n\t\t\t\t\t5):\n\t\t\t\t\t856\u2013\n\t\t\t\t\t869."},{"issue":"2","key":"i1551-6776-26-7-675-b31","series-title":"Addict Biol","first-page":"219","article-title":"In vivo and in vitro potency studies of 6beta-naltrexol, the major human metabolite of naltrexone","volume":"7","year":"2002","unstructured":"Porter\n              SJ,\n            \n            \n              Somogyi\n              AA,\n            \n            \n              White\n              JM.\n            \n          \n          In vivo and in vitro potency studies of 6beta-naltrexol, the major human metabolite of naltrexone.\n\t\t\t\t\tAddict Biol.\n\t\t\t\t\t2002;\n\t\t\t\t\t7(\n\t\t\t\t\t2):\n\t\t\t\t\t219\u2013\n\t\t\t\t\t225."},{"key":"i1551-6776-26-7-675-b32","series-title":"Eur J Pharm Sci","first-page":"1","article-title":"Species-specific lipophilicity of morphine antagonists","volume":"78","year":"2015","unstructured":"Maz\u00e1k\n              K,\n            \n            \n              Hosztafi\n              S,\n            \n            \n              Nosz\u00e1l\n              B.\n            \n          \n          Species-specific lipophilicity of morphine antagonists.\n\t\t\t\t\tEur J Pharm Sci.\n\t\t\t\t\t2015;\n\t\t\t\t\t78:\n\t\t\t\t\t1\u2013\n\t\t\t\t\t7."},{"issue":"4","key":"i1551-6776-26-7-675-b33","series-title":"AAPS J","first-page":"519","article-title":"BDDCS applied to over 900 drugs","volume":"13","year":"2011","unstructured":"Benet\n              LZ,\n            \n            \n              Broccatelli\n              F,\n            \n            \n              Oprea\n              TI.\n            \n          \n          BDDCS applied to over 900 drugs.\n\t\t\t\t\tAAPS J.\n\t\t\t\t\t2011;\n\t\t\t\t\t13(\n\t\t\t\t\t4):\n\t\t\t\t\t519\u2013\n\t\t\t\t\t547."},{"issue":"9, pt 2","key":"i1551-6776-26-7-675-b34","series-title":"J Clin Psychiatry","first-page":"15","article-title":"Bioequivalence, dose-proportionality, and pharmacokinetics of naltrexone after oral administration","volume":"45","year":"1984","unstructured":"Meyer\n              MC,\n            \n            \n              Straughn\n              AB,\n            \n            \n              Lo\n              MW,\n            \n          \n          .\n\t\t\t\t\tBioequivalence, dose-proportionality, and pharmacokinetics of naltrexone after oral administration.\n\t\t\t\t\tJ Clin Psychiatry.\n\t\t\t\t\t1984;\n\t\t\t\t\t45(\n\t\t\t\t\t9, pt 2):\n\t\t\t\t\t15\u2013\n\t\t\t\t\t19."},{"issue":"3","key":"i1551-6776-26-7-675-b35","series-title":"Clin Pharmacol Ther","first-page":"315","article-title":"Naltrexone: disposition, metabolism, and effects after acute and chronic dosing","volume":"20","year":"1976","unstructured":"Verebey\n              K,\n            \n            \n              Volavka\n              J,\n            \n            \n              Mule\n              SJ,\n            \n            \n              Resnick\n              RB.\n            \n          \n          Naltrexone: disposition, metabolism, and effects after acute and chronic dosing.\n\t\t\t\t\tClin Pharmacol Ther.\n\t\t\t\t\t1976;\n\t\t\t\t\t20(\n\t\t\t\t\t3):\n\t\t\t\t\t315\u2013\n\t\t\t\t\t328."},{"issue":"5","key":"i1551-6776-26-7-675-b36","series-title":"Br J Pharmacol","first-page":"465","article-title":"Kinetics and inhibition of the formation of 6beta-naltrexol from naltrexone in human liver cytosol","volume":"50","year":"2000","unstructured":"Porter\n              SJ,\n            \n            \n              Somogyi\n              AA,\n            \n            \n              White\n              JM.\n            \n          \n          Kinetics and inhibition of the formation of 6beta-naltrexol from naltrexone in human liver cytosol.\n\t\t\t\t\tBr J Pharmacol.\n\t\t\t\t\t2000;\n\t\t\t\t\t50(\n\t\t\t\t\t5):\n\t\t\t\t\t465\u2013\n\t\t\t\t\t471."},{"issue":"15","key":"i1551-6776-26-7-675-b37","series-title":"Bioorg Med Chem Lett","first-page":"3592","article-title":"Opioids and efflux transporters, part 4: influence of N-substitution on P-glycoprotein substrate activity of noroxymorphone analogues","volume":"24","year":"2014","unstructured":"Metcalf\n              MD,\n            \n            \n              Rosicky\n              AD,\n            \n            \n              Hassan\n              HE,\n            \n          \n          .\n\t\t\t\t\tOpioids and efflux transporters, part 4: influence of N-substitution on P-glycoprotein substrate activity of noroxymorphone analogues.\n\t\t\t\t\tBioorg Med Chem Lett.\n\t\t\t\t\t2014;\n\t\t\t\t\t24(\n\t\t\t\t\t15):\n\t\t\t\t\t3592\u2013\n\t\t\t\t\t3595."},{"issue":"5","key":"i1551-6776-26-7-675-b38","series-title":"Fundam Clin Pharmacol","first-page":"543","article-title":"P-glycoprotein is not involved in the differential oral potency of naloxone and naltrexone","volume":"23","year":"2009","unstructured":"Kanaan\n              M,\n            \n            \n              Daali\n              Y,\n            \n            \n              Dayer\n              P,\n            \n            \n              Desmeules\n              J.\n            \n          \n          P-glycoprotein is not involved in the differential oral potency of naloxone and naltrexone.\n\t\t\t\t\tFundam Clin Pharmacol.\n\t\t\t\t\t2009;\n\t\t\t\t\t23(\n\t\t\t\t\t5):\n\t\t\t\t\t543\u2013\n\t\t\t\t\t548."},{"issue":"9","key":"i1551-6776-26-7-675-b39","series-title":"Drug Metab Dispos","first-page":"1589","article-title":"Preclinical disposition (in vitro) of novel \u03bc-opioid receptor selective antagonists","volume":"39","year":"2011","unstructured":"Mitra\n              P,\n            \n            \n              Venitz\n              J,\n            \n            \n              Yuan\n              Y,\n            \n          \n          .\n\t\t\t\t\tPreclinical disposition (in vitro) of novel \u03bc-opioid receptor selective antagonists.\n\t\t\t\t\tDrug Metab Dispos.\n\t\t\t\t\t2011;\n\t\t\t\t\t39(\n\t\t\t\t\t9):\n\t\t\t\t\t1589\u2013\n\t\t\t\t\t1596."},{"issue":"3","key":"i1551-6776-26-7-675-b40","series-title":"Clin Pharmacokinet","first-page":"189","article-title":"Drugs, diseases and altered gastric emptying","volume":"1","year":"1976","unstructured":"Nimmo\n              WS.\n            \n          \n          Drugs, diseases and altered gastric emptying.\n\t\t\t\t\tClin Pharmacokinet.\n\t\t\t\t\t1976;\n\t\t\t\t\t1(\n\t\t\t\t\t3):\n\t\t\t\t\t189\u2013\n\t\t\t\t\t203."},{"issue":"1\u20132","key":"i1551-6776-26-7-675-b41","series-title":"Auton Neurosci","first-page":"99","article-title":"Gastrointestinal disturbances in eating disorders: clinical and neurobiological aspects","volume":"129","year":"2006","unstructured":"Zipfel\n              S,\n            \n            \n              Sammet\n              I,\n            \n            \n              Rapps\n              N,\n            \n          \n          .\n\t\t\t\t\tGastrointestinal disturbances in eating disorders: clinical and neurobiological aspects.\n\t\t\t\t\tAuton Neurosci.\n\t\t\t\t\t2006;\n\t\t\t\t\t129(\n\t\t\t\t\t1\u20132):\n\t\t\t\t\t99\u2013\n\t\t\t\t\t106."},{"issue":"7","key":"i1551-6776-26-7-675-b42","series-title":"Nat Med","first-page":"859","article-title":"Gut microbiome and serum metabolome alterations in obesity and after weight-loss intervention","volume":"23","year":"2017","unstructured":"Liu\n              R,\n            \n            \n              Hong\n              J,\n            \n            \n              Xu\n              X,\n            \n          \n          .\n\t\t\t\t\tGut microbiome and serum metabolome alterations in obesity and after weight-loss intervention.\n\t\t\t\t\tNat Med.\n\t\t\t\t\t2017;\n\t\t\t\t\t23(\n\t\t\t\t\t7):\n\t\t\t\t\t859\u2013\n\t\t\t\t\t868."},{"issue":"1","key":"i1551-6776-26-7-675-b43","series-title":"Psychiatr Clin North Am","first-page":"93","article-title":"The microbiome and eating disorders","volume":"42","year":"2019","unstructured":"Seitz\n              J,\n            \n            \n              Trinh\n              S,\n            \n            \n              Herpertz-Dahlmann\n              B.\n            \n          \n          The microbiome and eating disorders.\n\t\t\t\t\tPsychiatr Clin North Am.\n\t\t\t\t\t2019;\n\t\t\t\t\t42(\n\t\t\t\t\t1):\n\t\t\t\t\t93\u2013\n\t\t\t\t\t103."},{"issue":"10","key":"i1551-6776-26-7-675-b44","series-title":"Drug Metab Dispos","first-page":"1557","article-title":"Microbiome disturbances and autism spectrum disorders","volume":"43","year":"2015","unstructured":"Rosenfeld\n              CS.\n            \n          \n          Microbiome disturbances and autism spectrum disorders.\n\t\t\t\t\tDrug Metab Dispos.\n\t\t\t\t\t2015;\n\t\t\t\t\t43(\n\t\t\t\t\t10):\n\t\t\t\t\t1557\u2013\n\t\t\t\t\t1571."},{"issue":"8","key":"i1551-6776-26-7-675-b45","series-title":"Mol Psychiatry","first-page":"826","article-title":"Pharmacological differentiation of opioid receptor antagonists by molecular and functional imaging of target occupancy and food reward-related brain activation in humans","volume":"16","year":"2011","unstructured":"Rabiner\n              EA,\n            \n            \n              Beaver\n              J,\n            \n            \n              Makwana\n              A,\n            \n          \n          .\n\t\t\t\t\tPharmacological differentiation of opioid receptor antagonists by molecular and functional imaging of target occupancy and food reward-related brain activation in humans.\n\t\t\t\t\tMol Psychiatry.\n\t\t\t\t\t2011;\n\t\t\t\t\t16(\n\t\t\t\t\t8):\n\t\t\t\t\t826\u2013\n\t\t\t\t\t835;\n\t\t\t\t\t785."},{"issue":"5","key":"i1551-6776-26-7-675-b46","series-title":"Paediatr Drugs","first-page":"357","article-title":"Drug dose selection in pediatric obesity: available information for the most commonly prescribed drugs to children","volume":"21","year":"2019","unstructured":"Kyler\n              KE,\n            \n            \n              Wagner\n              J,\n            \n            \n              Hosey-Cojocari\n              C,\n            \n          \n          .\n\t\t\t\t\tDrug dose selection in pediatric obesity: available information for the most commonly prescribed drugs to children.\n\t\t\t\t\tPaediatr Drugs.\n\t\t\t\t\t2019;\n\t\t\t\t\t21(\n\t\t\t\t\t5):\n\t\t\t\t\t357\u2013\n\t\t\t\t\t369."},{"issue":"5","key":"i1551-6776-26-7-675-b47","series-title":"Pediatr Clin North Am","first-page":"1001","article-title":"Pediatric pharmacokinetics: human development and drug disposition","volume":"59","year":"2012","unstructured":"Funk\n              RS,\n            \n            \n              Brown\n              JT,\n            \n            \n              Abdel-Rahman\n              SM.\n            \n          \n          Pediatric pharmacokinetics: human development and drug disposition.\n\t\t\t\t\tPediatr Clin North Am.\n\t\t\t\t\t2012;\n\t\t\t\t\t59(\n\t\t\t\t\t5):\n\t\t\t\t\t1001\u2013\n\t\t\t\t\t1016."},{"issue":"6","key":"i1551-6776-26-7-675-b48","series-title":"Pediatr Rev","first-page":"258","article-title":"Pediatric pharmacokinetics","volume":"34","year":"2013","unstructured":"Wagner\n              J,\n            \n            \n              Abdel-Rahman\n              SM.\n            \n          \n          Pediatric pharmacokinetics.\n\t\t\t\t\tPediatr Rev.\n\t\t\t\t\t2013;\n\t\t\t\t\t34(\n\t\t\t\t\t6):\n\t\t\t\t\t258\u2013\n\t\t\t\t\t269."},{"issue":"9","key":"i1551-6776-26-7-675-b49","series-title":"Nutrients","first-page":"3895","article-title":"Anorexia nervosa and body fat distribution: a systematic review","volume":"6","year":"2014","unstructured":"El Ghoch\n              M,\n            \n            \n              Calugi\n              S,\n            \n            \n              Lamburghini\n              S,\n            \n            \n              Dalle Grave\n              R.\n            \n          \n          Anorexia nervosa and body fat distribution: a systematic review.\n\t\t\t\t\tNutrients.\n\t\t\t\t\t2014;\n\t\t\t\t\t6(\n\t\t\t\t\t9):\n\t\t\t\t\t3895\u2013\n\t\t\t\t\t3912."},{"issue":"7","key":"i1551-6776-26-7-675-b50","series-title":"Int J Eat Disord","first-page":"856","article-title":"Body composition in men with anorexia nervosa: longitudinal study","volume":"50","year":"2017","unstructured":"El Ghoch\n              M,\n            \n            \n              Calugi\n              S,\n            \n            \n              Milanese\n              C,\n            \n          \n          .\n\t\t\t\t\tBody composition in men with anorexia nervosa: longitudinal study.\n\t\t\t\t\tInt J Eat Disord.\n\t\t\t\t\t2017;\n\t\t\t\t\t50(\n\t\t\t\t\t7):\n\t\t\t\t\t856\u2013\n\t\t\t\t\t860."},{"issue":"6","key":"i1551-6776-26-7-675-b51","series-title":"Clin Nutr","first-page":"1224","article-title":"Regional fat distribution in adolescent and adult females with anorexia nervosa: a longitudinal study","volume":"34","year":"2015","unstructured":"El Ghoch\n              M,\n            \n            \n              Milanese\n              C,\n            \n            \n              Calugi\n              S,\n            \n          \n          .\n\t\t\t\t\tRegional fat distribution in adolescent and adult females with anorexia nervosa: a longitudinal study.\n\t\t\t\t\tClin Nutr.\n\t\t\t\t\t2015;\n\t\t\t\t\t34(\n\t\t\t\t\t6):\n\t\t\t\t\t1224\u2013\n\t\t\t\t\t1232."},{"issue":"12","key":"i1551-6776-26-7-675-b52","series-title":"Clin Pharmacokinet","first-page":"1577","article-title":"Influence of morbid obesity on the pharmacokinetics of morphine, morphine-3-glucuronide, and morphine-6-glucuronide","volume":"56","year":"2017","unstructured":"de Hoogd\n              S,\n            \n            \n              V\u00e4litalo\n              PAJ,\n            \n            \n              Dahan\n              A,\n            \n          \n          .\n\t\t\t\t\tInfluence of morbid obesity on the pharmacokinetics of morphine, morphine-3-glucuronide, and morphine-6-glucuronide.\n\t\t\t\t\tClin Pharmacokinet.\n\t\t\t\t\t2017;\n\t\t\t\t\t56(\n\t\t\t\t\t12):\n\t\t\t\t\t1577\u2013\n\t\t\t\t\t1587."},{"issue":"3","key":"i1551-6776-26-7-675-b53","series-title":"Anesthesiology","first-page":"470","article-title":"Effects of age on plasma protein binding of sufentanil","volume":"72","year":"1990","unstructured":"Meistelman\n              C,\n            \n            \n              Benhamou\n              D,\n            \n            \n              Barre\n              J,\n            \n          \n          .\n\t\t\t\t\tEffects of age on plasma protein binding of sufentanil.\n\t\t\t\t\tAnesthesiology.\n\t\t\t\t\t1990;\n\t\t\t\t\t72(\n\t\t\t\t\t3):\n\t\t\t\t\t470\u2013\n\t\t\t\t\t473."},{"issue":"3","key":"i1551-6776-26-7-675-b54","series-title":"Br J Clin Pharmacol","first-page":"344","article-title":"Effect of age and plasma concentrations of albumin and alpha 1-acid glycoprotein on protein binding of disopyramide","volume":"16","year":"1983","unstructured":"Holt\n              DW,\n            \n            \n              Hayler\n              AM,\n            \n            \n              Healey\n              GF.\n            \n          \n          Effect of age and plasma concentrations of albumin and alpha 1-acid glycoprotein on protein binding of disopyramide.\n\t\t\t\t\tBr J Clin Pharmacol.\n\t\t\t\t\t1983;\n\t\t\t\t\t16(\n\t\t\t\t\t3):\n\t\t\t\t\t344\u2013\n\t\t\t\t\t345."},{"issue":"3","key":"i1551-6776-26-7-675-b55","series-title":"Pediatr Res","first-page":"409","article-title":"Ontogeny of plasma proteins, albumin and binding of diazepam, cyclosporine, and deltamethrin","volume":"79","year":"2016","unstructured":"Sethi\n              PK,\n            \n            \n              White\n              CA,\n            \n            \n              Cummings\n              BS,\n            \n          \n          .\n\t\t\t\t\tOntogeny of plasma proteins, albumin and binding of diazepam, cyclosporine, and deltamethrin.\n\t\t\t\t\tPediatr Res.\n\t\t\t\t\t2016;\n\t\t\t\t\t79(\n\t\t\t\t\t3):\n\t\t\t\t\t409\u2013\n\t\t\t\t\t415."},{"issue":"3","key":"i1551-6776-26-7-675-b56","series-title":"Nutrients","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3390\/nu9030225","article-title":"Micronutrient status in 153 patients with anorexia nervosa","volume":"9","year":"2017","unstructured":"Achamrah\n              N,\n            \n            \n              Co\u00ebffier\n              M,\n            \n            \n              Rimbert\n              A,\n            \n          \n          .\n\t\t\t\t\tMicronutrient status in 153 patients with anorexia nervosa.\n\t\t\t\t\tNutrients.\n\t\t\t\t\t2017;\n\t\t\t\t\t9(\n\t\t\t\t\t3):\n\t\t\t\t\t225.\n\t\t\t\t\t10.3390\/nu9030225"},{"issue":"11","key":"i1551-6776-26-7-675-b57","series-title":"Dig Dis Sci","first-page":"2977","article-title":"Hepatic complications of anorexia nervosa","volume":"62","year":"2017","unstructured":"Rosen\n              E,\n            \n            \n              Bakshi\n              N,\n            \n            \n              Watters\n              A,\n            \n          \n          .\n\t\t\t\t\tHepatic complications of anorexia nervosa.\n\t\t\t\t\tDig Dis Sci.\n\t\t\t\t\t2017;\n\t\t\t\t\t62(\n\t\t\t\t\t11):\n\t\t\t\t\t2977\u2013\n\t\t\t\t\t2981."},{"issue":"10","key":"i1551-6776-26-7-675-b58","series-title":"Arch Pediatr Adolesc Med","first-page":"1118","article-title":"Malnutrition in hospitalized pediatric patients. Current prevalence","volume":"149","year":"1995","unstructured":"Hendricks\n              KM,\n            \n            \n              Duggan\n              C,\n            \n            \n              Gallagher\n              L,\n            \n          \n          .\n\t\t\t\t\tMalnutrition in hospitalized pediatric patients. Current prevalence.\n\t\t\t\t\tArch Pediatr Adolesc Med.\n\t\t\t\t\t1995;\n\t\t\t\t\t149(\n\t\t\t\t\t10):\n\t\t\t\t\t1118\u2013\n\t\t\t\t\t1122."},{"key":"i1551-6776-26-7-675-b59","series-title":"NIDA Res Monogr","first-page":"105","article-title":"The metabolism of naltrexone in man","volume":"28","year":"1981","unstructured":"Wall\n              ME,\n            \n            \n              Brine\n              DR,\n            \n            \n              Perez-Reyes\n              M.\n            \n          \n          The metabolism of naltrexone in man.\n\t\t\t\t\tNIDA Res Monogr.\n\t\t\t\t\t1981;\n\t\t\t\t\t28:\n\t\t\t\t\t105\u2013\n\t\t\t\t\t131."},{"issue":"3","key":"i1551-6776-26-7-675-b60","series-title":"Res Commun Chem Pathol Pharmacol","first-page":"455","article-title":"Carbon-13 nuclear magnetic resonance identification of 2-hydroxy-3-O-methyl-6beta-naltrexol as a minor naltrexone metabolite","volume":"22","year":"1978","unstructured":"Brine\n              GA,\n            \n            \n              Brine\n              DR,\n            \n            \n              Welch\n              CD,\n            \n          \n          .\n\t\t\t\t\tCarbon-13 nuclear magnetic resonance identification of 2-hydroxy-3-O-methyl-6beta-naltrexol as a minor naltrexone metabolite.\n\t\t\t\t\tRes Commun Chem Pathol Pharmacol.\n\t\t\t\t\t1978;\n\t\t\t\t\t22(\n\t\t\t\t\t3):\n\t\t\t\t\t455\u2013\n\t\t\t\t\t464."},{"issue":"3","key":"i1551-6776-26-7-675-b61","series-title":"Res Commun Chem Pathol Pharmacol","first-page":"413","article-title":"The identification and measurement of two new metabolites of naltrexone in human urine","volume":"20","year":"1978","unstructured":"Cone\n              EJ,\n            \n            \n              Gorodetzky\n              CW,\n            \n            \n              Darwin\n              WD,\n            \n          \n          .\n\t\t\t\t\tThe identification and measurement of two new metabolites of naltrexone in human urine.\n\t\t\t\t\tRes Commun Chem Pathol Pharmacol.\n\t\t\t\t\t1978;\n\t\t\t\t\t20(\n\t\t\t\t\t3):\n\t\t\t\t\t413\u2013\n\t\t\t\t\t433."},{"issue":"4","key":"i1551-6776-26-7-675-b62","series-title":"Neuropsychopharmacology","first-page":"596","article-title":"A pharmaco-kinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone","volume":"27","year":"2002","unstructured":"Mason\n              BJ,\n            \n            \n              Goodman\n              AM,\n            \n            \n              Dixon\n              RM,\n            \n          \n          .\n\t\t\t\t\tA pharmaco-kinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone.\n\t\t\t\t\tNeuropsychopharmacology.\n\t\t\t\t\t2002;\n\t\t\t\t\t27(\n\t\t\t\t\t4):\n\t\t\t\t\t596\u2013\n\t\t\t\t\t606."},{"issue":"9","key":"i1551-6776-26-7-675-b63","series-title":"Alcohol Clin Exp Res","first-page":"1385","article-title":"Serum 6-beta-naltrexol levels are related to alcohol responses in heavy drinkers","volume":"24","year":"2000","unstructured":"McCaul\n              ME,\n            \n            \n              Wand\n              GS,\n            \n            \n              Rohde\n              C,\n            \n            \n              Lee\n              SM.\n            \n          \n          Serum 6-beta-naltrexol levels are related to alcohol responses in heavy drinkers.\n\t\t\t\t\tAlcohol Clin Exp Res.\n\t\t\t\t\t2000;\n\t\t\t\t\t24(\n\t\t\t\t\t9):\n\t\t\t\t\t1385\u2013\n\t\t\t\t\t1391."},{"issue":"2","key":"i1551-6776-26-7-675-b64","series-title":"Drug Metabol Drug Interact","first-page":"161","article-title":"Effects of long-term treatment with naltrexone on hepatic enzyme activity","volume":"9","year":"1991","unstructured":"Pini\n              LA,\n            \n            \n              Ferretti\n              C,\n            \n            \n              Trenti\n              T,\n            \n          \n          .\n\t\t\t\t\tEffects of long-term treatment with naltrexone on hepatic enzyme activity.\n\t\t\t\t\tDrug Metabol Drug Interact.\n\t\t\t\t\t1991;\n\t\t\t\t\t9(\n\t\t\t\t\t2):\n\t\t\t\t\t161\u2013\n\t\t\t\t\t174."},{"issue":"6","key":"i1551-6776-26-7-675-b65","series-title":"Eur J Drug Metab Pharmacokinet","first-page":"707","article-title":"Effect of naltrexone hydrochloride on cytochrome P450 1A2, 2C9, 2D6, and 3A4 activity in human liver microsomes","volume":"43","year":"2018","unstructured":"AlRabiah\n              H,\n            \n            \n              Ahad\n              A,\n            \n            \n              Mostafa\n              GAE,\n            \n            \n              Al-Jenoobi\n              FI.\n            \n          \n          Effect of naltrexone hydrochloride on cytochrome P450 1A2, 2C9, 2D6, and 3A4 activity in human liver microsomes.\n\t\t\t\t\tEur J Drug Metab Pharmacokinet.\n\t\t\t\t\t2018;\n\t\t\t\t\t43(\n\t\t\t\t\t6):\n\t\t\t\t\t707\u2013\n\t\t\t\t\t713."},{"issue":"8","key":"i1551-6776-26-7-675-b66","series-title":"Biochem Pharmacol","first-page":"1277","article-title":"Carbonyl reductase provides the enzymatic basis of quinone detoxication in man","volume":"35","year":"1986","unstructured":"Wermuth\n              B,\n            \n            \n              Platts\n              KL,\n            \n            \n              Seidel\n              A,\n            \n            \n              Oesch\n              F.\n            \n          \n          Carbonyl reductase provides the enzymatic basis of quinone detoxication in man.\n\t\t\t\t\tBiochem Pharmacol.\n\t\t\t\t\t1986;\n\t\t\t\t\t35(\n\t\t\t\t\t8):\n\t\t\t\t\t1277\u2013\n\t\t\t\t\t1282."},{"issue":"2","key":"i1551-6776-26-7-675-b67","series-title":"Biochem Pharmacol","first-page":"221","article-title":"Reduction of drug ketones by dihydrodiol dehydrogenases, carbonyl reductase and aldehyde reductase of human liver","volume":"50","year":"1995","unstructured":"Ohara\n              H,\n            \n            \n              Miyabe\n              Y,\n            \n            \n              Deyashiki\n              Y,\n            \n          \n          .\n\t\t\t\t\tReduction of drug ketones by dihydrodiol dehydrogenases, carbonyl reductase and aldehyde reductase of human liver.\n\t\t\t\t\tBiochem Pharmacol.\n\t\t\t\t\t1995;\n\t\t\t\t\t50(\n\t\t\t\t\t2):\n\t\t\t\t\t221\u2013\n\t\t\t\t\t227."},{"issue":"12","key":"i1551-6776-26-7-675-b68","series-title":"J Pharm Pharmacol","first-page":"1601","article-title":"Carbonyl reduction of naltrexone and dolasetron by oxidoreductases isolated from human liver cytosol","volume":"56","year":"2004","unstructured":"Breyer-Pfaff\n              U,\n            \n            \n              Nill\n              K.\n            \n          \n          Carbonyl reduction of naltrexone and dolasetron by oxidoreductases isolated from human liver cytosol.\n\t\t\t\t\tJ Pharm Pharmacol.\n\t\t\t\t\t2004;\n\t\t\t\t\t56(\n\t\t\t\t\t12):\n\t\t\t\t\t1601\u2013\n\t\t\t\t\t1606."},{"issue":"pt 1","key":"i1551-6776-26-7-675-b69","series-title":"Biochem J","first-page":"67","article-title":"Human 3alpha-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones","volume":"351","year":"2000","unstructured":"Penning\n              TM,\n            \n            \n              Burczynski\n              ME,\n            \n            \n              Jez\n              JM,\n            \n          \n          .\n\t\t\t\t\tHuman 3alpha-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones.\n\t\t\t\t\tBiochem J.\n\t\t\t\t\t2000;\n\t\t\t\t\t351(\n\t\t\t\t\tpt 1):\n\t\t\t\t\t67\u2013\n\t\t\t\t\t77."},{"issue":"1\u20132","key":"i1551-6776-26-7-675-b70","series-title":"Mol Cell Endocrinol","first-page":"63","article-title":"Structure-function of human 3 alpha-hydroxysteroid dehydrogenases: genes and proteins","volume":"215","year":"2004","unstructured":"Penning\n              TM,\n            \n            \n              Jin\n              Y,\n            \n            \n              Steckelbroeck\n              S,\n            \n          \n          .\n\t\t\t\t\tStructure-function of human 3 alpha-hydroxysteroid dehydrogenases: genes and proteins.\n\t\t\t\t\tMol Cell Endocrinol.\n\t\t\t\t\t2004;\n\t\t\t\t\t215(\n\t\t\t\t\t1\u20132):\n\t\t\t\t\t63\u2013\n\t\t\t\t\t72."},{"issue":"2\u20135","key":"i1551-6776-26-7-675-b71","series-title":"J Steroid Biochem Mol Biol","first-page":"247","article-title":"Structure-function relationships in 3alpha-hydroxysteroid dehydrogenases: a comparison of the rat and human isoforms","volume":"85","year":"2003","unstructured":"Penning\n              TM,\n            \n            \n              Jin\n              Y,\n            \n            \n              Heredia\n              VV,\n            \n            \n              Lewis\n              M.\n            \n          \n          Structure-function relationships in 3alpha-hydroxysteroid dehydrogenases: a comparison of the rat and human isoforms.\n\t\t\t\t\tJ Steroid Biochem Mol Biol.\n\t\t\t\t\t2003;\n\t\t\t\t\t85(\n\t\t\t\t\t2\u20135):\n\t\t\t\t\t247\u2013\n\t\t\t\t\t255."},{"issue":"47","key":"i1551-6776-26-7-675-b72","series-title":"J Biol Chem","first-page":"34003","article-title":"3-ketosteroid reductase activity and expression by fetal rat osteoblasts","volume":"282","year":"2007","unstructured":"McCarthy\n              TL,\n            \n            \n              Hochberg\n              RB,\n            \n            \n              Labaree\n              DC,\n            \n            \n              Centrella\n              M.\n            \n          \n          3-ketosteroid reductase activity and expression by fetal rat osteoblasts.\n\t\t\t\t\tJ Biol Chem.\n\t\t\t\t\t2007;\n\t\t\t\t\t282(\n\t\t\t\t\t47):\n\t\t\t\t\t34003\u2013\n\t\t\t\t\t34012."},{"issue":"4","key":"i1551-6776-26-7-675-b73","series-title":"J Anal Toxicol","first-page":"212","article-title":"Naltrexone metabolism and concomitant drug concentrations in chronic pain patients","volume":"38","year":"2014","unstructured":"Liu\n              JC,\n            \n            \n              Ma\n              JD,\n            \n            \n              Morello\n              CM,\n            \n          \n          .\n\t\t\t\t\tNaltrexone metabolism and concomitant drug concentrations in chronic pain patients.\n\t\t\t\t\tJ Anal Toxicol.\n\t\t\t\t\t2014;\n\t\t\t\t\t38(\n\t\t\t\t\t4):\n\t\t\t\t\t212\u2013\n\t\t\t\t\t217."},{"issue":"2","key":"i1551-6776-26-7-675-b74","series-title":"Mol Pharmacol","first-page":"607","article-title":"Regulation of human 3 alpha-hydroxysteroid dehydrogenase (AKR1C4) expression by the liver X receptor alpha","volume":"73","year":"2008","unstructured":"Stayrook\n              KR,\n            \n            \n              Rogers\n              PM,\n            \n            \n              Savkur\n              RS,\n            \n          \n          .\n\t\t\t\t\tRegulation of human 3 alpha-hydroxysteroid dehydrogenase (AKR1C4) expression by the liver X receptor alpha.\n\t\t\t\t\tMol Pharmacol.\n\t\t\t\t\t2008;\n\t\t\t\t\t73(\n\t\t\t\t\t2):\n\t\t\t\t\t607\u2013\n\t\t\t\t\t612."},{"key":"i1551-6776-26-7-675-b75","series-title":"Chem Biol Interact","first-page":"167","article-title":"Sex hormones reduce NNK detoxification through inhibition of short-chain dehydrogenases\/reductases and aldo-keto reductases in vitro","volume":"276","year":"2017","unstructured":"Stapelfeld\n              C,\n            \n            \n              Maser\n              E.\n            \n          \n          Sex hormones reduce NNK detoxification through inhibition of short-chain dehydrogenases\/reductases and aldo-keto reductases in vitro.\n\t\t\t\t\tChem Biol Interact.\n\t\t\t\t\t2017;\n\t\t\t\t\t276:\n\t\t\t\t\t167\u2013\n\t\t\t\t\t173."},{"issue":"1","key":"i1551-6776-26-7-675-b76","series-title":"Muscle Nerve","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1002\/mus.10373","article-title":"Quantitative measurement of muscle fiber composition in a normal population","volume":"28","year":"2003","unstructured":"Toft\n              I,\n            \n            \n              Lindal\n              S,\n            \n            \n              B\u00f8naa\n              KH,\n            \n            \n              Jenssen\n              T.\n            \n          \n          Quantitative measurement of muscle fiber composition in a normal population.\n\t\t\t\t\tMuscle Nerve.\n\t\t\t\t\t2003;\n\t\t\t\t\t28(\n\t\t\t\t\t1):\n\t\t\t\t\t101\u2013\n\t\t\t\t\t108.\n\t\t\t\t\t10.1002\/mus.10373"},{"issue":"6","key":"i1551-6776-26-7-675-b77","series-title":"Pharmacogenetics","first-page":"763","article-title":"Characterization of a novel variant (S145C\/L311V) of 3alpha-hydroxysteroid\/dihydrodiol dehydrogenase in human liver","volume":"9","year":"1999","unstructured":"Kume\n              T,\n            \n            \n              Iwasa\n              H,\n            \n            \n              Shiraishi\n              H,\n            \n          \n          .\n\t\t\t\t\tCharacterization of a novel variant (S145C\/L311V) of 3alpha-hydroxysteroid\/dihydrodiol dehydrogenase in human liver.\n\t\t\t\t\tPharmacogenetics.\n\t\t\t\t\t1999;\n\t\t\t\t\t9(\n\t\t\t\t\t6):\n\t\t\t\t\t763\u2013\n\t\t\t\t\t771."},{"issue":"3","key":"i1551-6776-26-7-675-b78","series-title":"J Pharmacol Exp Ther","first-page":"533","article-title":"Naturally occurring variants of human aldo-keto reductases with reduced in vitro metabolism of daunorubicin and doxorubicin","volume":"335","year":"2010","unstructured":"Bains\n              OS,\n            \n            \n              Grigliatti\n              TA,\n            \n            \n              Reid\n              RE,\n            \n            \n              Riggs\n              KW.\n            \n          \n          Naturally occurring variants of human aldo-keto reductases with reduced in vitro metabolism of daunorubicin and doxorubicin.\n\t\t\t\t\tJ Pharmacol Exp Ther.\n\t\t\t\t\t2010;\n\t\t\t\t\t335(\n\t\t\t\t\t3):\n\t\t\t\t\t533\u2013\n\t\t\t\t\t545."},{"issue":"1","key":"i1551-6776-26-7-675-b79","series-title":"Nucleic Acids Res","first-page":"308","article-title":"dbSNP: the NCBI database of genetic variation","volume":"29","year":"2001","unstructured":"Sherry\n              ST,\n            \n            \n              Ward\n              MH,\n            \n            \n              Kholodov\n              M,\n            \n          \n          .\n\t\t\t\t\tdbSNP: the NCBI database of genetic variation.\n\t\t\t\t\tNucleic Acids Res.\n\t\t\t\t\t2001;\n\t\t\t\t\t29(\n\t\t\t\t\t1):\n\t\t\t\t\t308\u2013\n\t\t\t\t\t311."},{"issue":"1","key":"i1551-6776-26-7-675-b80","series-title":"Drug Metab Dispos","first-page":"73","article-title":"The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268)","volume":"26","year":"1998","unstructured":"Coffman\n              BL,\n            \n            \n              King\n              CD,\n            \n            \n              Rios\n              GR,\n            \n            \n              Tephly\n              TR.\n            \n          \n          The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268).\n\t\t\t\t\tDrug Metab Dispos.\n\t\t\t\t\t1998;\n\t\t\t\t\t26(\n\t\t\t\t\t1):\n\t\t\t\t\t73\u2013\n\t\t\t\t\t77."},{"issue":"1","key":"i1551-6776-26-7-675-b81","series-title":"Arch Biochem Biophys","first-page":"92","article-title":"The glucuronidation of exogenous and endogenous compounds by stably expressed rat and human UDP-glucuronosyltransferase 1.1","volume":"332","year":"1996","unstructured":"King\n              CD,\n            \n            \n              Green\n              MD,\n            \n            \n              Rios\n              GR,\n            \n          \n          .\n\t\t\t\t\tThe glucuronidation of exogenous and endogenous compounds by stably expressed rat and human UDP-glucuronosyltransferase 1.1.\n\t\t\t\t\tArch Biochem Biophys.\n\t\t\t\t\t1996;\n\t\t\t\t\t332(\n\t\t\t\t\t1):\n\t\t\t\t\t92\u2013\n\t\t\t\t\t100."},{"issue":"12","key":"i1551-6776-26-7-675-b82","series-title":"Drug Metab Dispos","first-page":"1389","article-title":"Glucuronidation of opioids, carboxylic acid-containing drugs, and hydroxylated xenobiotics catalyzed by expressed monkey UDP-glucuronosyltransferase 2B9 protein","volume":"25","year":"1997","unstructured":"Green\n              MD,\n            \n            \n              B\u00e9langer\n              G,\n            \n            \n              Hum\n              DW,\n            \n          \n          .\n\t\t\t\t\tGlucuronidation of opioids, carboxylic acid-containing drugs, and hydroxylated xenobiotics catalyzed by expressed monkey UDP-glucuronosyltransferase 2B9 protein.\n\t\t\t\t\tDrug Metab Dispos.\n\t\t\t\t\t1997;\n\t\t\t\t\t25(\n\t\t\t\t\t12):\n\t\t\t\t\t1389\u2013\n\t\t\t\t\t1394."},{"issue":"2","key":"i1551-6776-26-7-675-b83","series-title":"Drug Metab Dispos","first-page":"251","article-title":"Comparison of stably expressed rat UGT1.1 and UGT2B1 in the glucuronidation of opioid compounds","volume":"25","year":"1997","unstructured":"King\n              CD,\n            \n            \n              Rios\n              GR,\n            \n            \n              Green\n              MD,\n            \n          \n          .\n\t\t\t\t\tComparison of stably expressed rat UGT1.1 and UGT2B1 in the glucuronidation of opioid compounds.\n\t\t\t\t\tDrug Metab Dispos.\n\t\t\t\t\t1997;\n\t\t\t\t\t25(\n\t\t\t\t\t2):\n\t\t\t\t\t251\u2013\n\t\t\t\t\t255."},{"issue":"8","key":"i1551-6776-26-7-675-b84","series-title":"Am J Dis Child","first-page":"972","article-title":"The maturation of morphine clearance and metabolism","volume":"146","year":"1992","unstructured":"McRorie\n              TI,\n            \n            \n              Lynn\n              AM,\n            \n            \n              Nespeca\n              MK,\n            \n          \n          .\n\t\t\t\t\tThe maturation of morphine clearance and metabolism.\n\t\t\t\t\tAm J Dis Child.\n\t\t\t\t\t1992;\n\t\t\t\t\t146(\n\t\t\t\t\t8):\n\t\t\t\t\t972\u2013\n\t\t\t\t\t976."},{"issue":"6","key":"i1551-6776-26-7-675-b85","series-title":"Br J Clin Pharmacol","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/j.1365-2125.1980.tb01088.x","article-title":"Naloxone pharmacokinetics in the newborn","volume":"9","year":"1980","unstructured":"Moreland\n              TA,\n            \n            \n              Brice\n              JE,\n            \n            \n              Walker\n              CH,\n            \n            \n              Parija\n              AC.\n            \n          \n          Naloxone pharmacokinetics in the newborn.\n\t\t\t\t\tBr J Clin Pharmacol.\n\t\t\t\t\t1980;\n\t\t\t\t\t9(\n\t\t\t\t\t6):\n\t\t\t\t\t609\u2013\n\t\t\t\t\t612.\n\t\t\t\t\t10.1111\/j.1365-2125.1980.tb01088.x"},{"issue":"1","key":"i1551-6776-26-7-675-b86","series-title":"Clin Pharmacol Ther","first-page":"131","article-title":"Age- and genotype-dependent variability in the protein abundance and activity of six major uridine diphosphate-glucuronosyltransferases in human liver","volume":"105","year":"2019","unstructured":"Bhatt\n              DK,\n            \n            \n              Mehrotra\n              A,\n            \n            \n              Gaedigk\n              A,\n            \n          \n          .\n\t\t\t\t\tAge- and genotype-dependent variability in the protein abundance and activity of six major uridine diphosphate-glucuronosyltransferases in human liver.\n\t\t\t\t\tClin Pharmacol Ther.\n\t\t\t\t\t2019;\n\t\t\t\t\t105(\n\t\t\t\t\t1):\n\t\t\t\t\t131\u2013\n\t\t\t\t\t141."},{"issue":"6","key":"i1551-6776-26-7-675-b87","series-title":"Drug Metab Dispos","first-page":"506","article-title":"The urinary excretion profile of naltrexone and metabolites in man","volume":"2","year":"1974","unstructured":"Cone\n              EJ,\n            \n            \n              Gorodetzky\n              CW,\n            \n            \n              Yeh\n              SY.\n            \n          \n          The urinary excretion profile of naltrexone and metabolites in man.\n\t\t\t\t\tDrug Metab Dispos.\n\t\t\t\t\t1974;\n\t\t\t\t\t2(\n\t\t\t\t\t6):\n\t\t\t\t\t506\u2013\n\t\t\t\t\t512."},{"key":"i1551-6776-26-7-675-b88","series-title":"Neonatal and Pediatric Pharmacology: Therapeutic Principles in Practice","article-title":"Drug absorption, distribution, metabolism, excretion and transporters in newborns and children","unstructured":"Stancil\n              SL,\n            \n            \n              Chapron\n              A,\n            \n            \n              Abdel-Rahman\n              S.\n            \n          \n          Drug absorption, distribution, metabolism, excretion and transporters in newborns and children.\n\t\t\t\t\tNeonatal and Pediatric Pharmacology: Therapeutic Principles in Practice.\n\t\t\t\t\t5th ed.\n\t\t\t\t\t[In Press]"},{"issue":"4","key":"i1551-6776-26-7-675-b89","series-title":"Eur J Drug Metab Pharmacokinet","first-page":"225","article-title":"Pharmacokinetics and dialysability of naltrexone in patients undergoing hemodialysis","volume":"29","year":"2004","unstructured":"Kambia\n              NK,\n            \n            \n              Dine\n              T,\n            \n            \n              Odou\n              P,\n            \n          \n          .\n\t\t\t\t\tPharmacokinetics and dialysability of naltrexone in patients undergoing hemodialysis.\n\t\t\t\t\tEur J Drug Metab Pharmacokinet.\n\t\t\t\t\t2004;\n\t\t\t\t\t29(\n\t\t\t\t\t4):\n\t\t\t\t\t225\u2013\n\t\t\t\t\t230."},{"issue":"3","key":"i1551-6776-26-7-675-b90","series-title":"J Pharmacol Exp Ther","first-page":"712","article-title":"Drug inhibition of penicillin tubular secretion: concordance between in vitro and clinical findings","volume":"240","year":"1987","unstructured":"Nierenberg\n              DW.\n            \n          \n          Drug inhibition of penicillin tubular secretion: concordance between in vitro and clinical findings.\n\t\t\t\t\tJ Pharmacol Exp Ther.\n\t\t\t\t\t1987;\n\t\t\t\t\t240(\n\t\t\t\t\t3):\n\t\t\t\t\t712\u2013\n\t\t\t\t\t716."},{"issue":"4","key":"i1551-6776-26-7-675-b91","series-title":"Paediatr Drugs","first-page":"223","article-title":"Understanding developmental pharmacodynamics: importance for drug development and clinical practice","volume":"12","year":"2010","unstructured":"Mulla\n              H.\n            \n          \n          Understanding developmental pharmacodynamics: importance for drug development and clinical practice.\n\t\t\t\t\tPaediatr Drugs.\n\t\t\t\t\t2010;\n\t\t\t\t\t12(\n\t\t\t\t\t4):\n\t\t\t\t\t223\u2013\n\t\t\t\t\t233."},{"issue":"2","key":"i1551-6776-26-7-675-b92","series-title":"Clin Transl Sci","first-page":"140","article-title":"Considerations for implementing precision therapeutics for children","volume":"12","year":"2019","unstructured":"McLaughlin\n              MJ,\n            \n            \n              Wagner\n              J,\n            \n            \n              Shakhnovich\n              V,\n            \n          \n          .\n\t\t\t\t\tConsiderations for implementing precision therapeutics for children.\n\t\t\t\t\tClin Transl Sci.\n\t\t\t\t\t2019;\n\t\t\t\t\t12(\n\t\t\t\t\t2):\n\t\t\t\t\t140\u2013\n\t\t\t\t\t150."},{"issue":"5","key":"i1551-6776-26-7-675-b93","series-title":"J Am Acad Child Adolesc Psychiatry","first-page":"748","article-title":"Effects of the opiate antagonist, naltrexone, on binging antecedents and plasma beta-endorphin concentrations","volume":"33","year":"1994","unstructured":"Chatoor\n              I,\n            \n            \n              Herman\n              BH,\n            \n            \n              Hartzler\n              J.\n            \n          \n          Effects of the opiate antagonist, naltrexone, on binging antecedents and plasma beta-endorphin concentrations.\n\t\t\t\t\tJ Am Acad Child Adolesc Psychiatry.\n\t\t\t\t\t1994;\n\t\t\t\t\t33(\n\t\t\t\t\t5):\n\t\t\t\t\t748\u2013\n\t\t\t\t\t752."},{"issue":"7","key":"i1551-6776-26-7-675-b94","series-title":"J Nucl Med","first-page":"1207","article-title":"Duration of occupancy of opiate receptors by naltrexone","volume":"29","year":"1988","unstructured":"Lee\n              MC,\n            \n            \n              Wagner\n              HN,\n              Jr.,\n            \n            \n              Tanada\n              S,\n            \n          \n          .\n\t\t\t\t\tDuration of occupancy of opiate receptors by naltrexone.\n\t\t\t\t\tJ Nucl Med.\n\t\t\t\t\t1988;\n\t\t\t\t\t29(\n\t\t\t\t\t7):\n\t\t\t\t\t1207\u2013\n\t\t\t\t\t1211."},{"issue":"12","key":"i1551-6776-26-7-675-b95","series-title":"Pain Med","first-page":"1727","article-title":"6\u03b2-naltrexol, a peripherally selective opioid antagonist that inhibits morphine-induced slowing of gastrointestinal transit: an exploratory study","volume":"12","year":"2011","unstructured":"Yancey-Wrona\n              J,\n            \n            \n              Dallaire\n              B,\n            \n            \n              Bilsky\n              E,\n            \n          \n          .\n\t\t\t\t\t6\u03b2-naltrexol, a peripherally selective opioid antagonist that inhibits morphine-induced slowing of gastrointestinal transit: an exploratory study.\n\t\t\t\t\tPain Med.\n\t\t\t\t\t2011;\n\t\t\t\t\t12(\n\t\t\t\t\t12):\n\t\t\t\t\t1727\u2013\n\t\t\t\t\t1737."},{"issue":"11\u201312","key":"i1551-6776-26-7-675-b96","series-title":"Life Sci","first-page":"413","article-title":"6beta-naltrexol preferentially antagonizes opioid effects on gastrointestinal transit compared to antinociception in mice","volume":"85","year":"2009","unstructured":"Yancey-Wrona\n              JE,\n            \n            \n              Raymond\n              TJ,\n            \n            \n              Mercer\n              HK,\n            \n          \n          .\n\t\t\t\t\t6beta-naltrexol preferentially antagonizes opioid effects on gastrointestinal transit compared to antinociception in mice.\n\t\t\t\t\tLife Sci.\n\t\t\t\t\t2009;\n\t\t\t\t\t85(\n\t\t\t\t\t11\u201312):\n\t\t\t\t\t413\u2013\n\t\t\t\t\t420."},{"issue":"3","key":"i1551-6776-26-7-675-b97","series-title":"J Neurosci","first-page":"584","article-title":"Differential ontogeny of multiple opioid receptors (mu, delta, and kappa)","volume":"5","year":"1985","unstructured":"Spain\n              JW,\n            \n            \n              Roth\n              BL,\n            \n            \n              Coscia\n              CJ.\n            \n          \n          Differential ontogeny of multiple opioid receptors (mu, delta, and kappa).\n\t\t\t\t\tJ Neurosci.\n\t\t\t\t\t1985;\n\t\t\t\t\t5(\n\t\t\t\t\t3):\n\t\t\t\t\t584\u2013\n\t\t\t\t\t588."},{"issue":"2","key":"i1551-6776-26-7-675-b98","series-title":"Brain Res","first-page":"181","article-title":"Ontogeny and distribution of opioid receptors in the rat brainstem","volume":"549","year":"1991","unstructured":"Xia\n              Y,\n            \n            \n              Haddad\n              GG.\n            \n          \n          Ontogeny and distribution of opioid receptors in the rat brainstem.\n\t\t\t\t\tBrain Res.\n\t\t\t\t\t1991;\n\t\t\t\t\t549(\n\t\t\t\t\t2):\n\t\t\t\t\t181\u2013\n\t\t\t\t\t193."},{"issue":"1","key":"i1551-6776-26-7-675-b99","series-title":"Brain Res","first-page":"157","article-title":"Ontological development of opiate receptors in rodent brain","volume":"118","year":"1976","unstructured":"Clendeninn\n              NJ,\n            \n            \n              Petraitis\n              M,\n            \n            \n              Simon\n              EJ.\n            \n          \n          Ontological development of opiate receptors in rodent brain.\n\t\t\t\t\tBrain Res.\n\t\t\t\t\t1976;\n\t\t\t\t\t118(\n\t\t\t\t\t1):\n\t\t\t\t\t157\u2013\n\t\t\t\t\t160."},{"issue":"38","key":"i1551-6776-26-7-675-b100","series-title":"J Biol Chem","first-page":"32618","article-title":"Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G","volume":"280","year":"2005","unstructured":"Zhang\n              Y,\n            \n            \n              Wang\n              D,\n            \n            \n              Johnson\n              AD,\n            \n          \n          .\n\t\t\t\t\tAllelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G.\n\t\t\t\t\tJ Biol Chem.\n\t\t\t\t\t2005;\n\t\t\t\t\t280(\n\t\t\t\t\t38):\n\t\t\t\t\t32618\u2013\n\t\t\t\t\t32624."},{"issue":"16","key":"i1551-6776-26-7-675-b101","series-title":"Proc Natl Acad Sci U S A","first-page":"9608","article-title":"Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction","volume":"95","year":"1998","unstructured":"Bond\n              C,\n            \n            \n              LaForge\n              KS,\n            \n            \n              Tian\n              M,\n            \n          \n          .\n\t\t\t\t\tSingle-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction.\n\t\t\t\t\tProc Natl Acad Sci U S A.\n\t\t\t\t\t1998;\n\t\t\t\t\t95(\n\t\t\t\t\t16):\n\t\t\t\t\t9608\u2013\n\t\t\t\t\t9613."},{"issue":"8","key":"i1551-6776-26-7-675-b102","series-title":"Addiction","first-page":"1426","article-title":"Systematic review and meta-analysis of the moderating effect of rs1799971 in OPRM1, the mu-opioid receptor gene, on response to naltrexone treatment of alcohol use disorder","volume":"115","year":"2020","unstructured":"Hartwell\n              EE,\n            \n            \n              Feinn\n              R,\n            \n            \n              Morris\n              PE,\n            \n          \n          .\n\t\t\t\t\tSystematic review and meta-analysis of the moderating effect of rs1799971 in OPRM1, the mu-opioid receptor gene, on response to naltrexone treatment of alcohol use disorder.\n\t\t\t\t\tAddiction.\n\t\t\t\t\t2020;\n\t\t\t\t\t115(\n\t\t\t\t\t8):\n\t\t\t\t\t1426\u2013\n\t\t\t\t\t1437."},{"issue":"2","key":"i1551-6776-26-7-675-b103","series-title":"Arch Gen Psychiatry","first-page":"135","article-title":"An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study","volume":"65","year":"2008","unstructured":"Anton\n              RF,\n            \n            \n              Oroszi\n              G,\n            \n            \n              O'Malley\n              S,\n            \n          \n          .\n\t\t\t\t\tAn evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study.\n\t\t\t\t\tArch Gen Psychiatry.\n\t\t\t\t\t2008;\n\t\t\t\t\t65(\n\t\t\t\t\t2):\n\t\t\t\t\t135\u2013\n\t\t\t\t\t144."},{"issue":"4","key":"i1551-6776-26-7-675-b104","series-title":"Alcohol Clin Exp Res","first-page":"555","article-title":"Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study","volume":"31","year":"2007","unstructured":"Gelernter\n              J,\n            \n            \n              Gueorguieva\n              R,\n            \n            \n              Kranzler\n              HR,\n            \n          \n          .\n\t\t\t\t\tOpioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study.\n\t\t\t\t\tAlcohol Clin Exp Res.\n\t\t\t\t\t2007;\n\t\t\t\t\t31(\n\t\t\t\t\t4):\n\t\t\t\t\t555\u2013\n\t\t\t\t\t563."},{"issue":"2","key":"i1551-6776-26-7-675-b105","series-title":"Pharmacol Biochem Behav","first-page":"253","article-title":"Delta and kappa opioid receptor polymorphisms influence the effects of naltrexone on subjective responses to alcohol","volume":"103","year":"2012","unstructured":"Ashenhurst\n              JR,\n            \n            \n              Bujarski\n              S,\n            \n            \n              Ray\n              LA.\n            \n          \n          Delta and kappa opioid receptor polymorphisms influence the effects of naltrexone on subjective responses to alcohol.\n\t\t\t\t\tPharmacol Biochem Behav.\n\t\t\t\t\t2012;\n\t\t\t\t\t103(\n\t\t\t\t\t2):\n\t\t\t\t\t253\u2013\n\t\t\t\t\t259."},{"issue":"10","key":"i1551-6776-26-7-675-b106","series-title":"J Endocr Soc","first-page":"1235","article-title":"Effects of opioid antagonism on cerebrospinal fluid melanocortin peptides and cortisol levels in humans","volume":"1","year":"2017","unstructured":"Gordon\n              RJ,\n            \n            \n              Panigrahi\n              SK,\n            \n            \n              Meece\n              K,\n            \n          \n          .\n\t\t\t\t\tEffects of opioid antagonism on cerebrospinal fluid melanocortin peptides and cortisol levels in humans.\n\t\t\t\t\tJ Endocr Soc.\n\t\t\t\t\t2017;\n\t\t\t\t\t1(\n\t\t\t\t\t10):\n\t\t\t\t\t1235\u2013\n\t\t\t\t\t1246."},{"issue":"1","key":"i1551-6776-26-7-675-b107","series-title":"Life Sci","first-page":"55","article-title":"A preliminary study of beta endorphin during chronic naltrexone maintenance treatment in ex-opiate addicts","volume":"39","year":"1986","unstructured":"Kosten\n              TR,\n            \n            \n              Kreek\n              MJ,\n            \n            \n              Ragunath\n              J,\n            \n            \n              Kleber\n              HD.\n            \n          \n          A preliminary study of beta endorphin during chronic naltrexone maintenance treatment in ex-opiate addicts.\n\t\t\t\t\tLife Sci.\n\t\t\t\t\t1986;\n\t\t\t\t\t39(\n\t\t\t\t\t1):\n\t\t\t\t\t55\u2013\n\t\t\t\t\t59."},{"issue":"23\u201324","key":"i1551-6776-26-7-675-b108","series-title":"Psychopharmacology","first-page":"3869","article-title":"Opioid-receptor antagonism increases pain and decreases pleasure in obese and non-obese individuals","volume":"233","year":"2016","unstructured":"Price\n              RC,\n            \n            \n              Christou\n              NV,\n            \n            \n              Backman\n              SB,\n            \n          \n          .\n\t\t\t\t\tOpioid-receptor antagonism increases pain and decreases pleasure in obese and non-obese individuals.\n\t\t\t\t\tPsychopharmacology.\n\t\t\t\t\t2016;\n\t\t\t\t\t233(\n\t\t\t\t\t23\u201324):\n\t\t\t\t\t3869\u2013\n\t\t\t\t\t3879."},{"issue":"6","key":"i1551-6776-26-7-675-b109","series-title":"Am J Ment Retard","first-page":"414","article-title":"beta-Endorphin and ACTH are dissociated after self-injury in adults with developmental disabilities","volume":"108","year":"2003","unstructured":"Sandman\n              CA,\n            \n            \n              Touchette\n              P,\n            \n            \n              Lenjavi\n              M,\n            \n          \n          .\n\t\t\t\t\tbeta-Endorphin and ACTH are dissociated after self-injury in adults with developmental disabilities.\n\t\t\t\t\tAm J Ment Retard2003;\n\t\t\t\t\t108(\n\t\t\t\t\t6):\n\t\t\t\t\t414\u2013\n\t\t\t\t\t424."},{"issue":"2","key":"i1551-6776-26-7-675-b110","series-title":"Am J Ment Retard","first-page":"182","article-title":"Dissociation of POMC peptides after self-injury predicts responses to centrally acting opiate blockers","volume":"102","year":"1997","unstructured":"Sandman\n              CA,\n            \n            \n              Hetrick\n              W,\n            \n            \n              Taylor\n              DV,\n            \n            \n              Chicz-DeMet\n              A.\n            \n          \n          Dissociation of POMC peptides after self-injury predicts responses to centrally acting opiate blockers.\n\t\t\t\t\tAm J Ment Retard.\n\t\t\t\t\t1997;\n\t\t\t\t\t102(\n\t\t\t\t\t2):\n\t\t\t\t\t182\u2013\n\t\t\t\t\t199."},{"issue":"11","key":"i1551-6776-26-7-675-b111","series-title":"Neuropsychopharmacology","first-page":"2546","article-title":"Cortisol stress response in men and women modulated differentially by the mu-opioid receptor gene polymorphism OPRM1 A118G","volume":"40","year":"2015","unstructured":"Lovallo\n              WR,\n            \n            \n              Enoch\n              MA,\n            \n            \n              Acheson\n              A,\n            \n          \n          .\n\t\t\t\t\tCortisol stress response in men and women modulated differentially by the mu-opioid receptor gene polymorphism OPRM1 A118G.\n\t\t\t\t\tNeuropsychopharmacology.\n\t\t\t\t\t2015;\n\t\t\t\t\t40(\n\t\t\t\t\t11):\n\t\t\t\t\t2546\u2013\n\t\t\t\t\t2554."},{"issue":"6","key":"i1551-6776-26-7-675-b112","series-title":"Health Aff (Millwood)","first-page":"w706","article-title":"Equity in private insurance coverage for substance abuse: a perspective on parity","volume":"26","year":"2007","unstructured":"Barry\n              CL,\n            \n            \n              Sindelar\n              JL.\n            \n          \n          Equity in private insurance coverage for substance abuse: a perspective on parity.\n\t\t\t\t\tHealth Aff (Millwood).\n\t\t\t\t\t2007;\n\t\t\t\t\t26(\n\t\t\t\t\t6):\n\t\t\t\t\tw706\u2013\n\t\t\t\t\tw716."},{"issue":"8","key":"i1551-6776-26-7-675-b113","series-title":"Health Aff (Millwood)","first-page":"1216","article-title":"Medicaid benefits for addiction treatment expanded after implementation of the Affordable Care Act","volume":"37","year":"2018","unstructured":"Andrews\n              CM,\n            \n            \n              Grogan\n              CM,\n            \n            \n              Smith\n              BT,\n            \n          \n          .\n\t\t\t\t\tMedicaid benefits for addiction treatment expanded after implementation of the Affordable Care Act.\n\t\t\t\t\tHealth Aff (Millwood).\n\t\t\t\t\t2018;\n\t\t\t\t\t37(\n\t\t\t\t\t8):\n\t\t\t\t\t1216\u2013\n\t\t\t\t\t1222."},{"issue":"12","key":"i1551-6776-26-7-675-b114","series-title":"Health Aff (Millwood)","first-page":"2289","article-title":"Survey highlights differences in medicaid coverage for substance use treatment and opioid use disorder medications","volume":"35","year":"2016","unstructured":"Grogan\n              CM,\n            \n            \n              Andrews\n              C,\n            \n            \n              Abraham\n              A,\n            \n          \n          .\n\t\t\t\t\tSurvey highlights differences in medicaid coverage for substance use treatment and opioid use disorder medications.\n\t\t\t\t\tHealth Aff (Millwood).\n\t\t\t\t\t2016;\n\t\t\t\t\t35(\n\t\t\t\t\t12):\n\t\t\t\t\t2289\u2013\n\t\t\t\t\t2296."},{"issue":"9","key":"i1551-6776-26-7-675-b115","series-title":"NIDA Res Monogr","first-page":"67","article-title":"Patient response to naltrexone: issues of acceptance, treatment effects, and frequency of administration","year":"1976","unstructured":"Curran\n              S,\n            \n            \n              Savage\n              C.\n            \n          \n          Patient response to naltrexone: issues of acceptance, treatment effects, and frequency of administration.\n\t\t\t\t\tNIDA Res Monogr.\n\t\t\t\t\t1976(\n\t\t\t\t\t9):\n\t\t\t\t\t67\u2013\n\t\t\t\t\t69."},{"issue":"6","key":"i1551-6776-26-7-675-b116","series-title":"J Subst Abuse Treat","first-page":"529","article-title":"Naltrexone pharmacotherapy for opioid dependent federal probationers","volume":"14","year":"1997","unstructured":"Cornish\n              JW,\n            \n            \n              Metzger\n              D,\n            \n            \n              Woody\n              GE,\n            \n          \n          .\n\t\t\t\t\tNaltrexone pharmacotherapy for opioid dependent federal probationers.\n\t\t\t\t\tJ Subst Abuse Treat.\n\t\t\t\t\t1997;\n\t\t\t\t\t14(\n\t\t\t\t\t6):\n\t\t\t\t\t529\u2013\n\t\t\t\t\t534."},{"issue":"3","key":"i1551-6776-26-7-675-b117","series-title":"Arch Gen Psychiatry","first-page":"335","article-title":"Clinical evaluation of naltrexone treatment of opiate-dependent individuals: report of the National Research Council Committee on Clinical Evaluation of Narcotic Antagonists","volume":"35","year":"1978","unstructured":"Clinical evaluation of naltrexone treatment of opiate-dependent individuals: report of the National Research Council Committee on Clinical Evaluation of Narcotic Antagonists.\n\t\t\t\t\tArch Gen Psychiatry.\n\t\t\t\t\t1978;\n\t\t\t\t\t35(\n\t\t\t\t\t3):\n\t\t\t\t\t335\u2013\n\t\t\t\t\t340."},{"issue":"1","key":"i1551-6776-26-7-675-b118","series-title":"Isr J Psychiatry Relat Sci","first-page":"36","article-title":"A naltrexone double blind placebo controlled study in Israel","volume":"29","year":"1992","unstructured":"Lerner\n              A,\n            \n            \n              Sigal\n              M,\n            \n            \n              Bacalu\n              A,\n            \n          \n          .\n\t\t\t\t\tA naltrexone double blind placebo controlled study in Israel.\n\t\t\t\t\tIsr J Psychiatry Relat Sci.\n\t\t\t\t\t1992;\n\t\t\t\t\t29(\n\t\t\t\t\t1):\n\t\t\t\t\t36\u2013\n\t\t\t\t\t43."},{"issue":"12","key":"i1551-6776-26-7-675-b119","series-title":"Biol Psychiatry","first-page":"935","article-title":"The efficacy of naltrexone in preventing reabuse of heroin after detoxification","volume":"35","year":"1994","unstructured":"Shufman\n              EN,\n            \n            \n              Porat\n              S,\n            \n            \n              Witztum\n              E,\n            \n          \n          .\n\t\t\t\t\tThe efficacy of naltrexone in preventing reabuse of heroin after detoxification.\n\t\t\t\t\tBiol Psychiatry.\n\t\t\t\t\t1994;\n\t\t\t\t\t35(\n\t\t\t\t\t12):\n\t\t\t\t\t935\u2013\n\t\t\t\t\t945."},{"issue":"2","key":"i1551-6776-26-7-675-b120","series-title":"J Subst Abuse Treat","first-page":"147","article-title":"Availability of addiction medications in private health plans","volume":"34","year":"2008","unstructured":"Horgan\n              CM,\n            \n            \n              Reif\n              S,\n            \n            \n              Hodgkin\n              D,\n            \n          \n          .\n\t\t\t\t\tAvailability of addiction medications in private health plans.\n\t\t\t\t\tJ Subst Abuse Treat.\n\t\t\t\t\t2008;\n\t\t\t\t\t34(\n\t\t\t\t\t2):\n\t\t\t\t\t147\u2013\n\t\t\t\t\t156."},{"issue":"1\u20133","key":"i1551-6776-26-7-675-b121","series-title":"Drug Alcohol Depend","first-page":"345","article-title":"Alcohol and opioid dependence medications: prescription trends, overall and by physician specialty","volume":"99","year":"2009","unstructured":"Mark\n              TL,\n            \n            \n              Kassed\n              CA,\n            \n            \n              Vandivort-Warren\n              R,\n            \n          \n          .\n\t\t\t\t\tAlcohol and opioid dependence medications: prescription trends, overall and by physician specialty.\n\t\t\t\t\tDrug Alcohol Depend.\n\t\t\t\t\t2009;\n\t\t\t\t\t99(\n\t\t\t\t\t1\u20133):\n\t\t\t\t\t345\u2013\n\t\t\t\t\t349."},{"issue":"25","key":"i1551-6776-26-7-675-b122","series-title":"NIDA Res Monogr","first-page":"26","article-title":"Naltrexone and behavior therapy for heroin addiction","year":"1979","unstructured":"Rawson\n              RA,\n            \n            \n              Glazer\n              M,\n            \n            \n              Callahan\n              EJ,\n            \n            \n              Liberman\n              RP.\n            \n          \n          Naltrexone and behavior therapy for heroin addiction.\n\t\t\t\t\tNIDA Res Monogr.\n\t\t\t\t\t1979(\n\t\t\t\t\t25):\n\t\t\t\t\t26\u2013\n\t\t\t\t\t43."},{"issue":"1","key":"i1551-6776-26-7-675-b123","series-title":"J Stud Alcohol Drugs","first-page":"143","article-title":"Adoption of injectable naltrexone in U.S. substance use disorder treatment programs","volume":"76","year":"2015","unstructured":"Aletraris\n              L,\n            \n            \n              Bond Edmond\n              M,\n            \n            \n              Roman\n              PM.\n            \n          \n          Adoption of injectable naltrexone in U.S. substance use disorder treatment programs.\n\t\t\t\t\tJ Stud Alcohol Drugs.\n\t\t\t\t\t2015;\n\t\t\t\t\t76(\n\t\t\t\t\t1):\n\t\t\t\t\t143\u2013\n\t\t\t\t\t151."},{"issue":"8","key":"i1551-6776-26-7-675-b124","series-title":"Br J Addict","first-page":"983","article-title":"Follow-up after a six-month maintenance period on naltrexone versus placebo in heroin addicts","volume":"86","year":"1991","unstructured":"San\n              L,\n            \n            \n              Pomarol\n              G,\n            \n            \n              Peri\n              JM,\n            \n          \n          .\n\t\t\t\t\tFollow-up after a six-month maintenance period on naltrexone versus placebo in heroin addicts.\n\t\t\t\t\tBr J Addict.\n\t\t\t\t\t1991;\n\t\t\t\t\t86(\n\t\t\t\t\t8):\n\t\t\t\t\t983\u2013\n\t\t\t\t\t990."},{"issue":"6","key":"i1551-6776-26-7-675-b125","series-title":"Eur J Hosp Pharm","first-page":"352","article-title":"Compatibility of caffeine, carvedilol, clomipramine hydrochloride, folic acid, hydrochlorothiazide, loperamide hydrochloride, methotrexate, nadolol, naltrexone hydrochloride and pentoxifylline in SyrSpend SF PH4 oral suspensions","volume":"23","year":"2016","unstructured":"Polonini\n              HC,\n            \n            \n              Silva\n              SL,\n            \n            \n              de Almeida\n              TR,\n            \n          \n          .\n\t\t\t\t\tCompatibility of caffeine, carvedilol, clomipramine hydrochloride, folic acid, hydrochlorothiazide, loperamide hydrochloride, methotrexate, nadolol, naltrexone hydrochloride and pentoxifylline in SyrSpend SF PH4 oral suspensions.\n\t\t\t\t\tEur J Hosp Pharm.\n\t\t\t\t\t2016;\n\t\t\t\t\t23(\n\t\t\t\t\t6):\n\t\t\t\t\t352\u2013\n\t\t\t\t\t358."},{"issue":"11","key":"i1551-6776-26-7-675-b126","series-title":"Ann Pharmacother","first-page":"1291","article-title":"Formulation and stability of naltrexone oral liquid for rapid withdrawal from methadone","volume":"31","year":"1997","unstructured":"Fawcett\n              JP,\n            \n            \n              Morgan\n              NC,\n            \n            \n              Woods\n              DJ.\n            \n          \n          Formulation and stability of naltrexone oral liquid for rapid withdrawal from methadone.\n\t\t\t\t\tAnn Pharmacother.\n\t\t\t\t\t1997;\n\t\t\t\t\t31(\n\t\t\t\t\t11):\n\t\t\t\t\t1291\u2013\n\t\t\t\t\t1295."},{"issue":"3","key":"i1551-6776-26-7-675-b127","series-title":"J Am Acad Dermatol","first-page":"e139","article-title":"Inexpensive compounding of low dose naltrexone (LDN) with orange juice","volume":"85","year":"2019","unstructured":"Bronfenbrener\n              R.\n            \n          \n          Inexpensive compounding of low dose naltrexone (LDN) with orange juice.\n\t\t\t\t\tJ Am Acad Dermatol.\n\t\t\t\t\t2019;\n\t\t\t\t\t85(\n\t\t\t\t\t3):\n\t\t\t\t\te139."},{"issue":"4","key":"i1551-6776-26-7-675-b128","series-title":"Hong Kong J Psychiatry","first-page":"2","article-title":"Efficacy of naltrexone hydrochloride for preventing relapse among opiate-dependent patients after detoxification","volume":"11","year":"2001","unstructured":"Guo\n              S,\n            \n            \n              Jiang\n              Z,\n            \n            \n              Wu\n              Y.\n            \n          \n          Efficacy of naltrexone hydrochloride for preventing relapse among opiate-dependent patients after detoxification.\n\t\t\t\t\tHong Kong J Psychiatry.\n\t\t\t\t\t2001;\n\t\t\t\t\t11(\n\t\t\t\t\t4):\n\t\t\t\t\t2\u2013\n\t\t\t\t\t8."},{"issue":"4","key":"i1551-6776-26-7-675-b129","series-title":"J Subst Abuse Treat","first-page":"285","article-title":"Naltrexone for heroin dependence treatment in St. Petersburg, Russia","volume":"26","year":"2004","unstructured":"Krupitsky\n              EM,\n            \n            \n              Zvartau\n              EE,\n            \n            \n              Masalov\n              DV,\n            \n          \n          .\n\t\t\t\t\tNaltrexone for heroin dependence treatment in St. Petersburg, Russia.\n\t\t\t\t\tJ Subst Abuse Treat.\n\t\t\t\t\t2004;\n\t\t\t\t\t26(\n\t\t\t\t\t4):\n\t\t\t\t\t285\u2013\n\t\t\t\t\t294."},{"issue":"4","key":"i1551-6776-26-7-675-b130","series-title":"J Subst Abuse Treat","first-page":"319","article-title":"Naltrexone with or without fluoxetine for preventing relapse to heroin addiction in St. Petersburg, Russia","volume":"31","year":"2006","unstructured":"Krupitsky\n              EM,\n            \n            \n              Zvartau\n              EE,\n            \n            \n              Masalov\n              DV,\n            \n          \n          .\n\t\t\t\t\tNaltrexone with or without fluoxetine for preventing relapse to heroin addiction in St. Petersburg, Russia.\n\t\t\t\t\tJ Subst Abuse Treat.\n\t\t\t\t\t2006;\n\t\t\t\t\t31(\n\t\t\t\t\t4):\n\t\t\t\t\t319\u2013\n\t\t\t\t\t328."},{"issue":"21","key":"i1551-6776-26-7-675-b131","series-title":"Life Sci","first-page":"2717","article-title":"Naltrexone plus benzodiazepine aids abstinence in opioid-dependent patients","volume":"77","year":"2005","unstructured":"Stella\n              L,\n            \n            \n              D'Ambra\n              C,\n            \n            \n              Mazzeo\n              F,\n            \n          \n          .\n\t\t\t\t\tNaltrexone plus benzodiazepine aids abstinence in opioid-dependent patients.\n\t\t\t\t\tLife Sci.\n\t\t\t\t\t2005;\n\t\t\t\t\t77(\n\t\t\t\t\t21):\n\t\t\t\t\t2717\u2013\n\t\t\t\t\t2722."},{"issue":"9631","key":"i1551-6776-26-7-675-b132","series-title":"Lancet","first-page":"2192","article-title":"Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trial","volume":"371","year":"2008","unstructured":"Schottenfeld\n              RS,\n            \n            \n              Chawarski\n              MC,\n            \n            \n              Mazlan\n              M.\n            \n          \n          Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trial.\n\t\t\t\t\tLancet.\n\t\t\t\t\t2008;\n\t\t\t\t\t371(\n\t\t\t\t\t9631):\n\t\t\t\t\t2192\u2013\n\t\t\t\t\t2200."},{"issue":"9776","key":"i1551-6776-26-7-675-b133","series-title":"Lancet","first-page":"1506","article-title":"Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial","volume":"377","year":"2011","unstructured":"Krupitsky\n              E,\n            \n            \n              Nunes\n              EV,\n            \n            \n              Ling\n              W,\n            \n          \n          .\n\t\t\t\t\tInjectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.\n\t\t\t\t\tLancet.\n\t\t\t\t\t2011;\n\t\t\t\t\t377(\n\t\t\t\t\t9776):\n\t\t\t\t\t1506\u2013\n\t\t\t\t\t1513."},{"issue":"2","key":"i1551-6776-26-7-675-b134","series-title":"Am J Psychiatry","first-page":"129","article-title":"A randomized trial comparing extended-release injectable suspension and oral naltrexone, both combined with behavioral therapy, for the treatment of opioid use disorder","volume":"176","year":"2019","unstructured":"Sullivan\n              MA,\n            \n            \n              Bisaga\n              A,\n            \n            \n              Pavlicova\n              M,\n            \n          \n          .\n\t\t\t\t\tA randomized trial comparing extended-release injectable suspension and oral naltrexone, both combined with behavioral therapy, for the treatment of opioid use disorder.\n\t\t\t\t\tAm J Psychiatry.\n\t\t\t\t\t2019;\n\t\t\t\t\t176(\n\t\t\t\t\t2):\n\t\t\t\t\t129\u2013\n\t\t\t\t\t137."},{"issue":"11","key":"i1551-6776-26-7-675-b135","series-title":"Arch Gen Psychiatry","first-page":"876","article-title":"Naltrexone in the treatment of alcohol dependence","volume":"49","year":"1992","unstructured":"Volpicelli\n              JR,\n            \n            \n              Alterman\n              AI,\n            \n            \n              Hayashida\n              M,\n            \n            \n              O'Brien\n              CP.\n            \n          \n          Naltrexone in the treatment of alcohol dependence.\n\t\t\t\t\tArch Gen Psychiatry.\n\t\t\t\t\t1992;\n\t\t\t\t\t49(\n\t\t\t\t\t11):\n\t\t\t\t\t876\u2013\n\t\t\t\t\t880."},{"issue":"5","key":"i1551-6776-26-7-675-b136","series-title":"JAMA Psychiatry","first-page":"430","article-title":"Naltrexone vs placebo for the treatment of alcohol dependence: a randomized clinical trial","volume":"72","year":"2015","unstructured":"Oslin\n              DW,\n            \n            \n              Leong\n              SH,\n            \n            \n              Lynch\n              KG,\n            \n          \n          .\n\t\t\t\t\tNaltrexone vs placebo for the treatment of alcohol dependence: a randomized clinical trial.\n\t\t\t\t\tJAMA Psychiatry.\n\t\t\t\t\t2015;\n\t\t\t\t\t72(\n\t\t\t\t\t5):\n\t\t\t\t\t430\u2013\n\t\t\t\t\t437."},{"issue":"11","key":"i1551-6776-26-7-675-b137","series-title":"Arch Gen Psychiatry","first-page":"881","article-title":"Naltrexone and coping skills therapy for alcohol dependence: a controlled study","volume":"49","year":"1992","unstructured":"O'Malley\n              SS,\n            \n            \n              Jaffe\n              AJ,\n            \n            \n              Chang\n              G,\n            \n          \n          .\n\t\t\t\t\tNaltrexone and coping skills therapy for alcohol dependence: a controlled study.\n\t\t\t\t\tArch Gen Psychiatry.\n\t\t\t\t\t1992;\n\t\t\t\t\t49(\n\t\t\t\t\t11):\n\t\t\t\t\t881\u2013\n\t\t\t\t\t887."},{"issue":"17","key":"i1551-6776-26-7-675-b138","series-title":"JAMA","first-page":"2003","article-title":"Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial","volume":"295","year":"2006","unstructured":"Anton\n              RF,\n            \n            \n              O'Malley\n              SS,\n            \n            \n              Ciraulo\n              DA,\n            \n          \n          .\n\t\t\t\t\tCombined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.\n\t\t\t\t\tJAMA.\n\t\t\t\t\t2006;\n\t\t\t\t\t295(\n\t\t\t\t\t17):\n\t\t\t\t\t2003\u2013\n\t\t\t\t\t2017."},{"issue":"13","key":"i1551-6776-26-7-675-b139","series-title":"JAMA","first-page":"1617","article-title":"Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial","volume":"293","year":"2005","unstructured":"Garbutt\n              JC,\n            \n            \n              Kranzler\n              HR,\n            \n            \n              O'Malley\n              SS,\n            \n          \n          .\n\t\t\t\t\tEfficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial.\n\t\t\t\t\tJAMA.\n\t\t\t\t\t2005;\n\t\t\t\t\t293(\n\t\t\t\t\t13):\n\t\t\t\t\t1617\u2013\n\t\t\t\t\t1625."},{"issue":"7","key":"i1551-6776-26-7-675-b140","series-title":"Alcohol Clin Exp Res","first-page":"1051","article-title":"Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial","volume":"28","year":"2004","unstructured":"Kranzler\n              HR,\n            \n            \n              Wesson\n              DR,\n            \n            \n              Billot\n              L.\n            \n          \n          Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial.\n\t\t\t\t\tAlcohol Clin Exp Res.\n\t\t\t\t\t2004;\n\t\t\t\t\t28(\n\t\t\t\t\t7):\n\t\t\t\t\t1051\u2013\n\t\t\t\t\t1059."},{"issue":"5","key":"i1551-6776-26-7-675-b141","series-title":"Obesity (Silver Spring)","first-page":"935","article-title":"A randomized, phase 3 trial of naltrexone SR\/bupropion SR on weight and obesity-related risk factors (COR-II)","volume":"21","year":"2013","unstructured":"Apovian\n              CM,\n            \n            \n              Aronne\n              L,\n            \n            \n              Rubino\n              D,\n            \n          \n          .\n\t\t\t\t\tA randomized, phase 3 trial of naltrexone SR\/bupropion SR on weight and obesity-related risk factors (COR-II).\n\t\t\t\t\tObesity (Silver Spring).\n\t\t\t\t\t2013;\n\t\t\t\t\t21(\n\t\t\t\t\t5):\n\t\t\t\t\t935\u2013\n\t\t\t\t\t943."},{"issue":"5","key":"i1551-6776-26-7-675-b142","series-title":"Clin Obes","first-page":"237","article-title":"Patient-reported quality of life in a randomized placebo-controlled trial of naltrexone\/bupropion for obesity","volume":"5","year":"2015","unstructured":"Kolotkin\n              RL,\n            \n            \n              Chen\n              S,\n            \n            \n              Klassen\n              P,\n            \n          \n          .\n\t\t\t\t\tPatient-reported quality of life in a randomized placebo-controlled trial of naltrexone\/bupropion for obesity.\n\t\t\t\t\tClin Obes.\n\t\t\t\t\t2015;\n\t\t\t\t\t5(\n\t\t\t\t\t5):\n\t\t\t\t\t237\u2013\n\t\t\t\t\t244."},{"issue":"12","key":"i1551-6776-26-7-675-b143","series-title":"Diabetes Care","first-page":"4022","article-title":"Effects of naltrexone sustained-release\/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes","volume":"36","year":"2013","unstructured":"Hollander\n              P,\n            \n            \n              Gupta\n              AK,\n            \n            \n              Plodkowski\n              R,\n            \n          \n          .\n\t\t\t\t\tEffects of naltrexone sustained-release\/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes.\n\t\t\t\t\tDiabetes Care.\n\t\t\t\t\t2013;\n\t\t\t\t\t36(\n\t\t\t\t\t12):\n\t\t\t\t\t4022\u2013\n\t\t\t\t\t4029."},{"issue":"1","key":"i1551-6776-26-7-675-b144","series-title":"Obesity (Silver Spring)","first-page":"110","article-title":"Weight loss with naltrexone SR\/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial","volume":"19","year":"2011","unstructured":"Wadden\n              TA,\n            \n            \n              Foreyt\n              JP,\n            \n            \n              Foster\n              GD,\n            \n          \n          .\n\t\t\t\t\tWeight loss with naltrexone SR\/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial.\n\t\t\t\t\tObesity (Silver Spring).\n\t\t\t\t\t2011;\n\t\t\t\t\t19(\n\t\t\t\t\t1):\n\t\t\t\t\t110\u2013\n\t\t\t\t\t120."},{"issue":"9741","key":"i1551-6776-26-7-675-b145","series-title":"Lancet","first-page":"595","article-title":"Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"376","year":"2010","unstructured":"Greenway\n              FL,\n            \n            \n              Fujioka\n              K,\n            \n            \n              Plodkowski\n              RA,\n            \n          \n          .\n\t\t\t\t\tEffect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.\n\t\t\t\t\tLancet.\n\t\t\t\t\t2010;\n\t\t\t\t\t376(\n\t\t\t\t\t9741):\n\t\t\t\t\t595\u2013\n\t\t\t\t\t605."},{"issue":"2","key":"i1551-6776-26-7-675-b146","series-title":"J Clin Psychopharmacol","first-page":"94","article-title":"A placebo-controlled, double-blind crossover study of naltrexone hydrochloride in outpatients with normal weight bulimia","volume":"9","year":"1989","unstructured":"Mitchell\n              JE,\n            \n            \n              Christenson\n              G,\n            \n            \n              Jennings\n              J,\n            \n          \n          .\n\t\t\t\t\tA placebo-controlled, double-blind crossover study of naltrexone hydrochloride in outpatients with normal weight bulimia.\n\t\t\t\t\tJ Clin Psychopharmacol.\n\t\t\t\t\t1989;\n\t\t\t\t\t9(\n\t\t\t\t\t2):\n\t\t\t\t\t94\u2013\n\t\t\t\t\t97."},{"issue":"4","key":"i1551-6776-26-7-675-b147","series-title":"Am J Clin Nutr","first-page":"865","article-title":"Effect of a tricyclic antidepressant and opiate antagonist on binge-eating behavior in normoweight bulimic and obese, binge-eating subjects","volume":"53","year":"1991","unstructured":"Alger\n              SA,\n            \n            \n              Schwalberg\n              MD,\n            \n            \n              Bigaouette\n              JM,\n            \n          \n          .\n\t\t\t\t\tEffect of a tricyclic antidepressant and opiate antagonist on binge-eating behavior in normoweight bulimic and obese, binge-eating subjects.\n\t\t\t\t\tAm J Clin Nutr.\n\t\t\t\t\t1991;\n\t\t\t\t\t53(\n\t\t\t\t\t4):\n\t\t\t\t\t865\u2013\n\t\t\t\t\t871."},{"issue":"3","key":"i1551-6776-26-7-675-b148","series-title":"Int Clin Psychopharmacol","first-page":"163","article-title":"Naltrexone use in the treatment of anorexia nervosa and bulimia nervosa","volume":"10","year":"1995","unstructured":"Marrazzi\n              MA,\n            \n            \n              Bacon\n              JP,\n            \n            \n              Kinzie\n              J,\n            \n            \n              Luby\n              ED.\n            \n          \n          Naltrexone use in the treatment of anorexia nervosa and bulimia nervosa.\n\t\t\t\t\tInt Clin Psychopharmacol.\n\t\t\t\t\t1995;\n\t\t\t\t\t10(\n\t\t\t\t\t3):\n\t\t\t\t\t163\u2013\n\t\t\t\t\t172."},{"issue":"4","key":"i1551-6776-26-7-675-b149","series-title":"Int J Pscyhiatry Med","first-page":"305","article-title":"Treatment of antidepressant-resistant bulimia with naltrexone","volume":"16","year":"1986","unstructured":"Jonas\n              JM,\n            \n            \n              Gold\n              MS.\n            \n          \n          Treatment of antidepressant-resistant bulimia with naltrexone.\n\t\t\t\t\tInt J Pscyhiatry Med.\n\t\t\t\t\t1986;\n\t\t\t\t\t16(\n\t\t\t\t\t4):\n\t\t\t\t\t305\u2013\n\t\t\t\t\t309."},{"issue":"2","key":"i1551-6776-26-7-675-b150","series-title":"Psychiatry Res","first-page":"195","article-title":"The use of opiate antagonists in treating bulimia: a study of low-dose versus high-dose naltrexone","volume":"24","year":"1988","unstructured":"Jonas\n              JM,\n            \n            \n              Gold\n              MS.\n            \n          \n          The use of opiate antagonists in treating bulimia: a study of low-dose versus high-dose naltrexone.\n\t\t\t\t\tPsychiatry Res.\n\t\t\t\t\t1988;\n\t\t\t\t\t24(\n\t\t\t\t\t2):\n\t\t\t\t\t195\u2013\n\t\t\t\t\t199."},{"issue":"5","key":"i1551-6776-26-7-675-b151","series-title":"Int J Obes","first-page":"347","article-title":"A controlled trial of naltrexone in obese humans","volume":"9","year":"1985","unstructured":"Malcolm\n              R,\n            \n            \n              O'Neil\n              PM,\n            \n            \n              Sexauer\n              JD,\n            \n          \n          .\n\t\t\t\t\tA controlled trial of naltrexone in obese humans.\n\t\t\t\t\tInt J Obes.\n\t\t\t\t\t1985;\n\t\t\t\t\t9(\n\t\t\t\t\t5):\n\t\t\t\t\t347\u2013\n\t\t\t\t\t353."},{"issue":"3","key":"i1551-6776-26-7-675-b152","series-title":"PloS One","first-page":"e0116231","article-title":"Contraceptive use and pregnancy outcomes among opioid drug-using women: a retrospective cohort study","volume":"10","year":"2015","unstructured":"Cornford\n              CS,\n            \n            \n              Close\n              HJ,\n            \n            \n              Bray\n              R,\n            \n          \n          .\n\t\t\t\t\tContraceptive use and pregnancy outcomes among opioid drug-using women: a retrospective cohort study.\n\t\t\t\t\tPloS One.\n\t\t\t\t\t2015;\n\t\t\t\t\t10(\n\t\t\t\t\t3):\n\t\t\t\t\te0116231."},{"issue":"1\u20134","key":"i1551-6776-26-7-675-b153","series-title":"Exp Clin Psychopharmacol","first-page":"242","article-title":"Naltrexone reduces self-injury and improves learning","volume":"1","year":"1993","unstructured":"Sandman\n              CA,\n            \n            \n              Hetrick\n              WP,\n            \n            \n              Taylor\n              DV,\n            \n          \n          .\n\t\t\t\t\tNaltrexone reduces self-injury and improves learning.\n\t\t\t\t\tExp Clin Psychopharmacol.\n\t\t\t\t\t1993;\n\t\t\t\t\t1(\n\t\t\t\t\t1\u20134):\n\t\t\t\t\t242\u2013\n\t\t\t\t\t258."},{"issue":"3","key":"i1551-6776-26-7-675-b154","series-title":"J Nerv Ment Dis","first-page":"192","article-title":"Naltrexone treatment of self-injurious thoughts and behaviors","volume":"184","year":"1996","unstructured":"Sonne\n              S,\n            \n            \n              Rubey\n              R,\n            \n            \n              Brady\n              K,\n            \n          \n          .\n\t\t\t\t\tNaltrexone treatment of self-injurious thoughts and behaviors.\n\t\t\t\t\tJ Nerv Ment Dis.\n\t\t\t\t\t1996;\n\t\t\t\t\t184(\n\t\t\t\t\t3):\n\t\t\t\t\t192\u2013\n\t\t\t\t\t195."},{"issue":"9","key":"i1551-6776-26-7-675-b155","series-title":"Arch Gen Psychiatry","first-page":"766","article-title":"Failure of naltrexone hydrochloride to reduce self-injurious and autistic behavior in mentally retarded adults: double-blind placebo-controlled studies","volume":"52","year":"1995","unstructured":"Willemsen-Swinkels\n              SH,\n            \n            \n              Buitelaar\n              JK,\n            \n            \n              Nijhof\n              GJ,\n            \n            \n              van England\n              H.\n            \n          \n          Failure of naltrexone hydrochloride to reduce self-injurious and autistic behavior in mentally retarded adults: double-blind placebo-controlled studies.\n\t\t\t\t\tArch Gen Psychiatry.\n\t\t\t\t\t1995;\n\t\t\t\t\t52(\n\t\t\t\t\t9):\n\t\t\t\t\t766\u2013\n\t\t\t\t\t773."},{"issue":"1","key":"i1551-6776-26-7-675-b156","series-title":"Am J Ment Retard","first-page":"93","article-title":"An orally administered opiate blocker, naltrexone, attenuates self-injurious behavior","volume":"95","year":"1990","unstructured":"Sandman\n              CA,\n            \n            \n              Barron\n              JL,\n            \n            \n              Colman\n              H.\n            \n          \n          An orally administered opiate blocker, naltrexone, attenuates self-injurious behavior.\n\t\t\t\t\tAm J Ment Retard.\n\t\t\t\t\t1990;\n\t\t\t\t\t95(\n\t\t\t\t\t1):\n\t\t\t\t\t93\u2013\n\t\t\t\t\t102."},{"issue":"7","key":"i1551-6776-26-7-675-b157","series-title":"Biol Psychiatry","first-page":"741","article-title":"Naltrexone attenuates self-injurious behavior in mentally retarded subjects","volume":"27","year":"1990","unstructured":"Kars\n              H,\n            \n            \n              Broekema\n              W,\n            \n            \n              Glaudemans-van Gelderen\n              I,\n            \n          \n          .\n\t\t\t\t\tNaltrexone attenuates self-injurious behavior in mentally retarded subjects.\n\t\t\t\t\tBiol Psychiatry.\n\t\t\t\t\t1990;\n\t\t\t\t\t27(\n\t\t\t\t\t7):\n\t\t\t\t\t741\u2013\n\t\t\t\t\t746."},{"issue":"3","key":"i1551-6776-26-7-675-b158","series-title":"Exp Clin Psychopharmacol","first-page":"269","article-title":"Sequential analysis of the effects of naltrexone on the environmental mediation of self-injurious behavior","volume":"9","year":"2001","unstructured":"Symons\n              FJ,\n            \n            \n              Tapp\n              J,\n            \n            \n              Wulfsberg\n              A,\n            \n          \n          .\n\t\t\t\t\tSequential analysis of the effects of naltrexone on the environmental mediation of self-injurious behavior.\n\t\t\t\t\tExp Clin Psychopharmacol.\n\t\t\t\t\t2001;\n\t\t\t\t\t9(\n\t\t\t\t\t3):\n\t\t\t\t\t269\u2013\n\t\t\t\t\t276."},{"issue":"6","key":"i1551-6776-26-7-675-b159","series-title":"J Clin Psychiatry","first-page":"233","article-title":"Naltrexone as a treatment for repetitive self-injurious behaviour: an open-label trial","volume":"57","year":"1996","unstructured":"Roth\n              AS,\n            \n            \n              Ostroff\n              RB,\n            \n            \n              Hoffman\n              RE.\n            \n          \n          Naltrexone as a treatment for repetitive self-injurious behaviour: an open-label trial.\n\t\t\t\t\tJ Clin Psychiatry.\n\t\t\t\t\t1996;\n\t\t\t\t\t57(\n\t\t\t\t\t6):\n\t\t\t\t\t233\u2013\n\t\t\t\t\t237."},{"issue":"1","key":"i1551-6776-26-7-675-b160","series-title":"Am J Ment Retard","first-page":"57","article-title":"Clinical effects of naltrexone on autistic behavior","volume":"97","year":"1992","unstructured":"Zingarelli\n              G,\n            \n            \n              Ellman\n              G,\n            \n            \n              Hom\n              A,\n            \n          \n          .\n\t\t\t\t\tClinical effects of naltrexone on autistic behavior.\n\t\t\t\t\tAm J Ment Retard.\n\t\t\t\t\t1992;\n\t\t\t\t\t97(\n\t\t\t\t\t1):\n\t\t\t\t\t57\u2013\n\t\t\t\t\t63."},{"issue":"4","key":"i1551-6776-26-7-675-b161","series-title":"Am J Ment Retard","first-page":"336","article-title":"Preliminary study of altered skin temperature at body sites associated with self-injurious behavior in adults who have developmental disabilities","volume":"106","year":"2001","unstructured":"Symons\n              FJ,\n            \n            \n              Sutton\n              KA,\n            \n            \n              Bodfish\n              JW.\n            \n          \n          Preliminary study of altered skin temperature at body sites associated with self-injurious behavior in adults who have developmental disabilities.\n\t\t\t\t\tAm J Ment Retard.\n\t\t\t\t\t2001;\n\t\t\t\t\t106(\n\t\t\t\t\t4):\n\t\t\t\t\t336\u2013\n\t\t\t\t\t343."},{"issue":"1","key":"i1551-6776-26-7-675-b162","series-title":"Am J Ment Retard","first-page":"85","article-title":"Opioid antagonist effects on self-injury in adults with mental retardation: response form and location as determinants of medication effects","volume":"99","year":"1994","unstructured":"Thompson\n              T,\n            \n            \n              Hackenberg\n              T,\n            \n            \n              Cerutti\n              D,\n            \n          \n          .\n\t\t\t\t\tOpioid antagonist effects on self-injury in adults with mental retardation: response form and location as determinants of medication effects.\n\t\t\t\t\tAm J Ment Retard.\n\t\t\t\t\t1994;\n\t\t\t\t\t99(\n\t\t\t\t\t1):\n\t\t\t\t\t85\u2013\n\t\t\t\t\t102."},{"issue":"4","key":"i1551-6776-26-7-675-b163","series-title":"Gastroenterology","first-page":"1264","article-title":"Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study","volume":"113","year":"1997","unstructured":"Wolfhagen\n              FH,\n            \n            \n              Sternieri\n              E,\n            \n            \n              Hop\n              WC,\n            \n          \n          .\n\t\t\t\t\tOral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study.\n\t\t\t\t\tGastroenterology.\n\t\t\t\t\t1997;\n\t\t\t\t\t113(\n\t\t\t\t\t4):\n\t\t\t\t\t1264\u2013\n\t\t\t\t\t1269."},{"issue":"7","key":"i1551-6776-26-7-675-b164","series-title":"World J Gastroenterol","first-page":"1125","article-title":"Effect of oral naltrexone on pruritus in cholestatic patients","volume":"12","year":"2006","unstructured":"Mansour-Ghanaei\n              F,\n            \n            \n              Taheri\n              A,\n            \n            \n              Froutan\n              H,\n            \n          \n          .\n\t\t\t\t\tEffect of oral naltrexone on pruritus in cholestatic patients.\n\t\t\t\t\tWorld J Gastroenterol.\n\t\t\t\t\t2006;\n\t\t\t\t\t12(\n\t\t\t\t\t7):\n\t\t\t\t\t1125\u2013\n\t\t\t\t\t1128."},{"issue":"9041","key":"i1551-6776-26-7-675-b165","series-title":"Lancet","first-page":"1552","article-title":"Randomised crossover trial of naltrexone in uraemic pruritus","volume":"348","year":"1996","unstructured":"Peer\n              G,\n            \n            \n              Kivity\n              S,\n            \n            \n              Agami\n              O,\n            \n          \n          .\n\t\t\t\t\tRandomised crossover trial of naltrexone in uraemic pruritus.\n\t\t\t\t\tLancet.\n\t\t\t\t\t1996;\n\t\t\t\t\t348(\n\t\t\t\t\t9041):\n\t\t\t\t\t1552\u2013\n\t\t\t\t\t1554."},{"issue":"3","key":"i1551-6776-26-7-675-b166","series-title":"J Am Soc Nephrol","first-page":"514","article-title":"Naltrexone does not relieve uremic pruritus: results of a randomized, double-blind, placebo-controlled crossover study","volume":"11","year":"2000","unstructured":"Pauli-Magnus\n              C,\n            \n            \n              Mikus\n              G,\n            \n            \n              Alscher\n              DM,\n            \n          \n          .\n\t\t\t\t\tNaltrexone does not relieve uremic pruritus: results of a randomized, double-blind, placebo-controlled crossover study.\n\t\t\t\t\tJ Am Soc Nephrol.\n\t\t\t\t\t2000;\n\t\t\t\t\t11(\n\t\t\t\t\t3):\n\t\t\t\t\t514\u2013\n\t\t\t\t\t519."},{"issue":"8","key":"i1551-6776-26-7-675-b167","series-title":"J Eur Acad Dermatol Venereol","first-page":"948","article-title":"Efficacy of oral naltrexone on pruritus in atopic eczema: a double-blind, placebo-controlled study","volume":"23","year":"2009","unstructured":"Malekzad\n              F,\n            \n            \n              Arbabi\n              M,\n            \n            \n              Mohtasham\n              N,\n            \n          \n          .\n\t\t\t\t\tEfficacy of oral naltrexone on pruritus in atopic eczema: a double-blind, placebo-controlled study.\n\t\t\t\t\tJ Eur Acad Dermatol Venereol.\n\t\t\t\t\t2009;\n\t\t\t\t\t23(\n\t\t\t\t\t8):\n\t\t\t\t\t948\u2013\n\t\t\t\t\t950."},{"issue":"4","key":"i1551-6776-26-7-675-b168","series-title":"Dermatology","first-page":"326","article-title":"A comparative study on the effects of naltrexone and loratadine on uremic pruritus","volume":"208","year":"2004","unstructured":"Legroux-Crespel\n              E,\n            \n            \n              Cl\u00e8des\n              J,\n            \n            \n              Misery\n              L.\n            \n          \n          A comparative study on the effects of naltrexone and loratadine on uremic pruritus.\n\t\t\t\t\tDermatology.\n\t\t\t\t\t2004;\n\t\t\t\t\t208(\n\t\t\t\t\t4):\n\t\t\t\t\t326\u2013\n\t\t\t\t\t330."},{"issue":"6","key":"i1551-6776-26-7-675-b169","series-title":"J Hepatol","first-page":"717","article-title":"Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study","volume":"37","year":"2002","unstructured":"Terg\n              R,\n            \n            \n              Coronel\n              E,\n            \n            \n              Sord\u00e1\n              J,\n            \n          \n          .\n\t\t\t\t\tEfficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study.\n\t\t\t\t\tJ Hepatol.\n\t\t\t\t\t2002;\n\t\t\t\t\t37(\n\t\t\t\t\t6):\n\t\t\t\t\t717\u2013\n\t\t\t\t\t722."},{"issue":"12","key":"i1551-6776-26-7-675-b170","series-title":"Int J Dermatol","first-page":"972","article-title":"Endogenous opioids, mu-opiate receptors and chloroquine-induced pruritus: a double-blind comparison of naltrexone and promethazine in patients with malaria fever who have an established history of generalized chloroquine-induced itching","volume":"43","year":"2004","unstructured":"Ajayi\n              AA,\n            \n            \n              Kolawole\n              BA,\n            \n            \n              Udoh\n              SJ.\n            \n          \n          Endogenous opioids, mu-opiate receptors and chloroquine-induced pruritus: a double-blind comparison of naltrexone and promethazine in patients with malaria fever who have an established history of generalized chloroquine-induced itching.\n\t\t\t\t\tInt J Dermatol.\n\t\t\t\t\t2004;\n\t\t\t\t\t43(\n\t\t\t\t\t12):\n\t\t\t\t\t972\u2013\n\t\t\t\t\t977."},{"issue":"3","key":"i1551-6776-26-7-675-b171","series-title":"J Behav Addict","first-page":"827","article-title":"The use of naltrexone in pathological and problem gambling: a UK case series","volume":"7","year":"2018","unstructured":"Ward\n              S,\n            \n            \n              Smith\n              N,\n            \n            \n              Bowden-Jones\n              H.\n            \n          \n          The use of naltrexone in pathological and problem gambling: a UK case series.\n\t\t\t\t\tJ Behav Addict.\n\t\t\t\t\t2018;\n\t\t\t\t\t7(\n\t\t\t\t\t3):\n\t\t\t\t\t827\u2013\n\t\t\t\t\t833."},{"issue":"3","key":"i1551-6776-26-7-675-b172","series-title":"Clin Neuropharmacol","first-page":"118","article-title":"Opioid antagonist naltrexone for the treatment of pathological gambling in Parkinson disease","volume":"35","year":"2012","unstructured":"Bosco\n              D,\n            \n            \n              Plastino\n              M,\n            \n            \n              Colica\n              C,\n            \n          \n          .\n\t\t\t\t\tOpioid antagonist naltrexone for the treatment of pathological gambling in Parkinson disease.\n\t\t\t\t\tClin Neuropharmacol.\n\t\t\t\t\t2012;\n\t\t\t\t\t35(\n\t\t\t\t\t3):\n\t\t\t\t\t118\u2013\n\t\t\t\t\t120."},{"issue":"7","key":"i1551-6776-26-7-675-b173","series-title":"Biol Psychiatry","first-page":"600","article-title":"A double-blind, placebo-controlled study of the opiate antagonist, naltrexone, in the treatment of kleptomania","volume":"65","year":"2009","unstructured":"Grant\n              JE,\n            \n            \n              Kim\n              SW,\n            \n            \n              Odlaug\n              BL.\n            \n          \n          A double-blind, placebo-controlled study of the opiate antagonist, naltrexone, in the treatment of kleptomania.\n\t\t\t\t\tBiol Psychiatry.\n\t\t\t\t\t2009;\n\t\t\t\t\t65(\n\t\t\t\t\t7):\n\t\t\t\t\t600\u2013\n\t\t\t\t\t606."},{"issue":"5","key":"i1551-6776-26-7-675-b174","series-title":"J Clin Psychiatry","first-page":"783","article-title":"A double-blind, placebo-controlled study of the opiate antagonist naltrexone in the treatment of pathological gambling urges","volume":"69","year":"2008","unstructured":"Grant\n              JE,\n            \n            \n              Kim\n              SW,\n            \n            \n              Hartman\n              BK.\n            \n          \n          A double-blind, placebo-controlled study of the opiate antagonist naltrexone in the treatment of pathological gambling urges.\n\t\t\t\t\tJ Clin Psychiatry.\n\t\t\t\t\t2008;\n\t\t\t\t\t69(\n\t\t\t\t\t5):\n\t\t\t\t\t783\u2013\n\t\t\t\t\t789."},{"issue":"2","key":"i1551-6776-26-7-675-b175","series-title":"Eur Addict Res","first-page":"70","article-title":"A randomised, double-blind, placebo-controlled trial of as-needed naltrexone in the treatment of pathological gambling","volume":"22","year":"2016","unstructured":"Kovanen\n              L,\n            \n            \n              Basnet\n              S,\n            \n            \n              Castr\u00e9n\n              S,\n            \n          \n          .\n\t\t\t\t\tA randomised, double-blind, placebo-controlled trial of as-needed naltrexone in the treatment of pathological gambling.\n\t\t\t\t\tEur Addict Res.\n\t\t\t\t\t2016;\n\t\t\t\t\t22(\n\t\t\t\t\t2):\n\t\t\t\t\t70\u2013\n\t\t\t\t\t79."},{"issue":"9","key":"i1551-6776-26-7-675-b176","series-title":"Neurology","first-page":"826","article-title":"Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study","volume":"83","year":"2014","unstructured":"Papay\n              K,\n            \n            \n              Xie\n              SX,\n            \n            \n              Stern\n              M,\n            \n          \n          .\n\t\t\t\t\tNaltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study.\n\t\t\t\t\tNeurology.\n\t\t\t\t\t2014;\n\t\t\t\t\t83(\n\t\t\t\t\t9):\n\t\t\t\t\t826\u2013\n\t\t\t\t\t833."},{"issue":"1","key":"i1551-6776-26-7-675-b177","series-title":"J Clin Psychopharmacol","first-page":"134","article-title":"The opiate antagonist, naltrexone, in the treatment of trichotillomania: results of a double-blind, placebo-controlled study","volume":"34","year":"2014","unstructured":"Grant\n              JE,\n            \n            \n              Odlaug\n              BL,\n            \n            \n              Schreiber\n              LR,\n            \n            \n              Kim\n              SW.\n            \n          \n          The opiate antagonist, naltrexone, in the treatment of trichotillomania: results of a double-blind, placebo-controlled study.\n\t\t\t\t\tJ Clin Psychopharmacol.\n\t\t\t\t\t2014;\n\t\t\t\t\t34(\n\t\t\t\t\t1):\n\t\t\t\t\t134\u2013\n\t\t\t\t\t138."},{"issue":"3","key":"i1551-6776-26-7-675-b178","series-title":"Am J Addict","first-page":"219","article-title":"A randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of concurrent alcohol use disorder and pathological gambling","volume":"18","year":"2009","unstructured":"Toneatto\n              T,\n            \n            \n              Brands\n              B,\n            \n            \n              Selby\n              P.\n            \n          \n          A randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of concurrent alcohol use disorder and pathological gambling.\n\t\t\t\t\tAm J Addict.\n\t\t\t\t\t2009;\n\t\t\t\t\t18(\n\t\t\t\t\t3):\n\t\t\t\t\t219\u2013\n\t\t\t\t\t225."},{"issue":"5","key":"i1551-6776-26-7-675-b179","series-title":"Addict Biol","first-page":"941","article-title":"Effects of naltrexone on adolescent alcohol cue reactivity and sensitivity: an initial randomized trial","volume":"19","year":"2014","unstructured":"Miranda\n              R,\n            \n            \n              Ray\n              L,\n            \n            \n              Blanchard\n              A,\n            \n          \n          .\n\t\t\t\t\tEffects of naltrexone on adolescent alcohol cue reactivity and sensitivity: an initial randomized trial.\n\t\t\t\t\tAddict Biol.\n\t\t\t\t\t2014;\n\t\t\t\t\t19(\n\t\t\t\t\t5):\n\t\t\t\t\t941\u2013\n\t\t\t\t\t954."},{"issue":"3","key":"i1551-6776-26-7-675-b180","series-title":"Addict Biol","first-page":"337","article-title":"A pilot study to assess the impact of naltrexone implant on accidental opiate overdose in \u201chigh-risk\u201d adolescent heroin users","volume":"8","year":"2003","unstructured":"Hulse\n              GK,\n            \n            \n              Tait\n              RJ.\n            \n          \n          A pilot study to assess the impact of naltrexone implant on accidental opiate overdose in \u201chigh-risk\u201d adolescent heroin users.\n\t\t\t\t\tAddict Biol.\n\t\t\t\t\t2003;\n\t\t\t\t\t8(\n\t\t\t\t\t3):\n\t\t\t\t\t337\u2013\n\t\t\t\t\t342."},{"issue":"9","key":"i1551-6776-26-7-675-b181","series-title":"Addiction","first-page":"1669","article-title":"Treatment of opioid dependence in adolescents and young adults with extended release naltrexone: preliminary case-series and feasibility","volume":"105","year":"2010","unstructured":"Fishman\n              MJ,\n            \n            \n              Winstanley\n              EL,\n            \n            \n              Curran\n              E,\n            \n          \n          .\n\t\t\t\t\tTreatment of opioid dependence in adolescents and young adults with extended release naltrexone: preliminary case-series and feasibility.\n\t\t\t\t\tAddiction.\n\t\t\t\t\t2010;\n\t\t\t\t\t105(\n\t\t\t\t\t9):\n\t\t\t\t\t1669\u2013\n\t\t\t\t\t1676."},{"issue":"5","key":"i1551-6776-26-7-675-b182","series-title":"J Clin Psychopharmacol","first-page":"389","article-title":"Naltrexone and self-injurious behavior: a retrospective population study","volume":"16","year":"1996","unstructured":"Casner\n              JA,\n            \n            \n              Weinheimer\n              B,\n            \n            \n              Gualtieri\n              CT.\n            \n          \n          Naltrexone and self-injurious behavior: a retrospective population study.\n\t\t\t\t\tJ Clin Psychopharmacol.\n\t\t\t\t\t1996;\n\t\t\t\t\t16(\n\t\t\t\t\t5):\n\t\t\t\t\t389\u2013\n\t\t\t\t\t394."},{"issue":"7","key":"i1551-6776-26-7-675-b183","series-title":"J Clin Psychiatry","first-page":"982","article-title":"Naltrexone in the treatment of adolescent sexual offenders","volume":"65","year":"2004","unstructured":"Ryback\n              RS.\n            \n          \n          Naltrexone in the treatment of adolescent sexual offenders.\n\t\t\t\t\tJ Clin Psychiatry.\n\t\t\t\t\t2004;\n\t\t\t\t\t65(\n\t\t\t\t\t7):\n\t\t\t\t\t982\u2013\n\t\t\t\t\t986."},{"issue":"6","key":"i1551-6776-26-7-675-b184","series-title":"J Am Acad Child Adolesc Psychiatr","first-page":"1283","article-title":"Naltrexone in autistic children: behavioral symptoms and attentional learning","volume":"32","year":"1993","unstructured":"Campbell\n              M,\n            \n            \n              Anderson\n              LT,\n            \n            \n              Small\n              AM,\n            \n          \n          .\n\t\t\t\t\tNaltrexone in autistic children: behavioral symptoms and attentional learning.\n\t\t\t\t\tJ Am Acad Child Adolesc Psychiatr.\n\t\t\t\t\t1993;\n\t\t\t\t\t32(\n\t\t\t\t\t6):\n\t\t\t\t\t1283\u2013\n\t\t\t\t\t1291."},{"issue":"6","key":"i1551-6776-26-7-675-b185","series-title":"Am J Ment Retard","first-page":"644","article-title":"Effects of naloxone and naltrexone on self-injury: a double-blind, placebo-controlled analysis","volume":"93","year":"1989","unstructured":"Barrett\n              RP,\n            \n            \n              Feinstein\n              C,\n            \n            \n              Hole\n              WT.\n            \n          \n          Effects of naloxone and naltrexone on self-injury: a double-blind, placebo-controlled analysis.\n\t\t\t\t\tAm J Ment Retard.\n\t\t\t\t\t1989;\n\t\t\t\t\t93(\n\t\t\t\t\t6):\n\t\t\t\t\t644\u2013\n\t\t\t\t\t651."},{"issue":"3","key":"i1551-6776-26-7-675-b186","series-title":"Psychiatry Res","first-page":"191","article-title":"Low-dose naltrexone effects on plasma chemistries and clinical symptoms in autism: a double-blind, placebo-controlled study","volume":"58","year":"1995","unstructured":"Bouvard\n              MP,\n            \n            \n              Leboyer\n              M,\n            \n            \n              Launay\n              JM,\n            \n          \n          .\n\t\t\t\t\tLow-dose naltrexone effects on plasma chemistries and clinical symptoms in autism: a double-blind, placebo-controlled study.\n\t\t\t\t\tPsychiatry Res.\n\t\t\t\t\t1995;\n\t\t\t\t\t58(\n\t\t\t\t\t3):\n\t\t\t\t\t191\u2013\n\t\t\t\t\t201."},{"issue":"1","key":"i1551-6776-26-7-675-b187","series-title":"Psychopharmacol Bull","first-page":"130","article-title":"Naltrexone in autistic children: a double-blind and placebo-controlled study","volume":"26","year":"1990","unstructured":"Campbell\n              M,\n            \n            \n              Anderson\n              LT,\n            \n            \n              Small\n              AM,\n            \n          \n          .\n\t\t\t\t\tNaltrexone in autistic children: a double-blind and placebo-controlled study.\n\t\t\t\t\tPsychopharmacol Bull.\n\t\t\t\t\t1990;\n\t\t\t\t\t26(\n\t\t\t\t\t1):\n\t\t\t\t\t130\u2013\n\t\t\t\t\t135."},{"issue":"2","key":"i1551-6776-26-7-675-b188","series-title":"J Autism Dev Disord","first-page":"309","article-title":"Brief report: a double-blind study of naltrexone in infantile autism","volume":"22","year":"1992","unstructured":"Leboyer\n              M,\n            \n            \n              Bouvard\n              MP,\n            \n            \n              Launay\n              JM,\n            \n          \n          .\n\t\t\t\t\tBrief report: a double-blind study of naltrexone in infantile autism.\n\t\t\t\t\tJ Autism Dev Disord.\n\t\t\t\t\t1992;\n\t\t\t\t\t22(\n\t\t\t\t\t2):\n\t\t\t\t\t309\u2013\n\t\t\t\t\t319."},{"issue":"2","key":"i1551-6776-26-7-675-b189","series-title":"Psychopharmacol Bull","first-page":"203","article-title":"Naltrexone plasma levels, clinical response and effect on weight in autistic children","volume":"30","year":"1994","unstructured":"Gonzalez\n              NM,\n            \n            \n              Campbell\n              M,\n            \n            \n              Small\n              AM,\n            \n          \n          .\n\t\t\t\t\tNaltrexone plasma levels, clinical response and effect on weight in autistic children.\n\t\t\t\t\tPsychopharmacol Bull.\n\t\t\t\t\t1994;\n\t\t\t\t\t30(\n\t\t\t\t\t2):\n\t\t\t\t\t203\u2013\n\t\t\t\t\t208."},{"issue":"3","key":"i1551-6776-26-7-675-b190","series-title":"Ann Ist Super Sanita","first-page":"351","article-title":"Opioid-immune interactions in autism: behavioural and immunological assessment during a double-blind treatment with naltrexone","volume":"32","year":"1996","unstructured":"Scifo\n              R,\n            \n            \n              Cioni\n              M,\n            \n            \n              Nicolosi\n              A,\n            \n          \n          .\n\t\t\t\t\tOpioid-immune interactions in autism: behavioural and immunological assessment during a double-blind treatment with naltrexone.\n\t\t\t\t\tAnn Ist Super Sanita.\n\t\t\t\t\t1996;\n\t\t\t\t\t32(\n\t\t\t\t\t3):\n\t\t\t\t\t351\u2013\n\t\t\t\t\t359."},{"issue":"5","key":"i1551-6776-26-7-675-b191","series-title":"J Child Adolesc Psychopharmacol","first-page":"396","article-title":"Effectiveness of naltrexone for treating pathologic skin picking behavior in an adolescent with Prader-Willi syndrome","volume":"22","year":"2012","unstructured":"Banga\n              A,\n            \n            \n              Connor\n              DF.\n            \n          \n          Effectiveness of naltrexone for treating pathologic skin picking behavior in an adolescent with Prader-Willi syndrome.\n\t\t\t\t\tJ Child Adolesc Psychopharmacol.\n\t\t\t\t\t2012;\n\t\t\t\t\t22(\n\t\t\t\t\t5):\n\t\t\t\t\t396\u2013\n\t\t\t\t\t398."},{"issue":"4","key":"i1551-6776-26-7-675-b192","series-title":"J Am Acad Child Adolesc Psychiatry","first-page":"870","article-title":"Naltrexone and fluoxetine in Prader-Willi syndrome","volume":"32","year":"1993","unstructured":"Benjamin\n              E,\n            \n            \n              Buot-Smith\n              T.\n            \n          \n          Naltrexone and fluoxetine in Prader-Willi syndrome.\n\t\t\t\t\tJ Am Acad Child Adolesc Psychiatry.\n\t\t\t\t\t1993;\n\t\t\t\t\t32(\n\t\t\t\t\t4):\n\t\t\t\t\t870\u2013\n\t\t\t\t\t873."},{"issue":"4","key":"i1551-6776-26-7-675-b193","series-title":"J Child Adolesc Psychopharmacol","first-page":"403","article-title":"Prader-Willi syndrome, management of impulsivity, and hyperphagia in an adolescent","volume":"26","year":"2016","unstructured":"Puri\n              MR,\n            \n            \n              Sahl\n              R,\n            \n            \n              Ogden\n              S,\n            \n            \n              Malik\n              S.\n            \n          \n          Prader-Willi syndrome, management of impulsivity, and hyperphagia in an adolescent.\n\t\t\t\t\tJ Child Adolesc Psychopharmacol.\n\t\t\t\t\t2016;\n\t\t\t\t\t26(\n\t\t\t\t\t4):\n\t\t\t\t\t403\u2013\n\t\t\t\t\t404."},{"issue":"5","key":"i1551-6776-26-7-675-b194","series-title":"J Clin Endocrinol Metab","first-page":"1229","article-title":"The effects of naltrexone, an oral beta-endorphin antagonist, in children with the Prader-Willi syndrome","volume":"63","year":"1986","unstructured":"Zlotkin\n              SH,\n            \n            \n              Fettes\n              IM,\n            \n            \n              Stallings\n              VA.\n            \n          \n          The effects of naltrexone, an oral beta-endorphin antagonist, in children with the Prader-Willi syndrome.\n\t\t\t\t\tJ Clin Endocrinol Metab.\n\t\t\t\t\t1986;\n\t\t\t\t\t63(\n\t\t\t\t\t5):\n\t\t\t\t\t1229\u2013\n\t\t\t\t\t1232."},{"issue":"4","key":"i1551-6776-26-7-675-b195","series-title":"J Clin Gastroenterol","first-page":"339","article-title":"Safety and tolerability of low-dose naltrexone therapy in children with moderate to severe Crohn's disease: a pilot study","volume":"47","year":"2013","unstructured":"Smith\n              JP,\n            \n            \n              Field\n              D,\n            \n            \n              Bingaman\n              SI,\n            \n          \n          .\n\t\t\t\t\tSafety and tolerability of low-dose naltrexone therapy in children with moderate to severe Crohn's disease: a pilot study.\n\t\t\t\t\tJ Clin Gastroenterol.\n\t\t\t\t\t2013;\n\t\t\t\t\t47(\n\t\t\t\t\t4):\n\t\t\t\t\t339\u2013\n\t\t\t\t\t345."},{"issue":"3","key":"i1551-6776-26-7-675-b196","series-title":"J Neuroimmune Pharmacol","first-page":"470","article-title":"Treatment of Complex Regional Pain Syndrome (CRPS) using low dose naltrexone (LDN)","volume":"8","year":"2013","unstructured":"Chopra\n              P,\n            \n            \n              Cooper\n              MS.\n            \n          \n          Treatment of Complex Regional Pain Syndrome (CRPS) using low dose naltrexone (LDN).\n\t\t\t\t\tJ Neuroimmune Pharmacol.\n\t\t\t\t\t2013;\n\t\t\t\t\t8(\n\t\t\t\t\t3):\n\t\t\t\t\t470\u2013\n\t\t\t\t\t476."},{"issue":"10","key":"i1551-6776-26-7-675-b197","series-title":"Trends Neurosci","first-page":"587","article-title":"kappa-opioid receptor\/dynorphin system: genetic and pharmaco-therapeutic implications for addiction","volume":"35","year":"2012","unstructured":"Butelman\n              ER,\n            \n            \n              Yuferov\n              V,\n            \n            \n              Kreek\n              MJ.\n            \n          \n          kappa-opioid receptor\/dynorphin system: genetic and pharmaco-therapeutic implications for addiction.\n\t\t\t\t\tTrends Neurosci.\n\t\t\t\t\t2012;\n\t\t\t\t\t35(\n\t\t\t\t\t10):\n\t\t\t\t\t587\u2013\n\t\t\t\t\t596."},{"issue":"2","key":"i1551-6776-26-7-675-b198","series-title":"J Clin Med Res","first-page":"41","article-title":"The opioid system and food intake: use of opiate antagonists in treatment of binge eating disorder and abnormal eating behavior","volume":"12","year":"2020","unstructured":"Valbrun\n              LP,\n            \n            \n              Zvonarev\n              V.\n            \n          \n          The opioid system and food intake: use of opiate antagonists in treatment of binge eating disorder and abnormal eating behavior.\n\t\t\t\t\tJ Clin Med Res.\n\t\t\t\t\t2020;\n\t\t\t\t\t12(\n\t\t\t\t\t2):\n\t\t\t\t\t41\u2013\n\t\t\t\t\t63."},{"issue":"2","key":"i1551-6776-26-7-675-b199","series-title":"Mol Pharmacol","first-page":"330","article-title":"Pharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptors","volume":"45","year":"1994","unstructured":"Raynor\n              K,\n            \n            \n              Kong\n              H,\n            \n            \n              Chen\n              Y,\n            \n          \n          .\n\t\t\t\t\tPharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptors.\n\t\t\t\t\tMol Pharmacol.\n\t\t\t\t\t1994;\n\t\t\t\t\t45(\n\t\t\t\t\t2):\n\t\t\t\t\t330\u2013\n\t\t\t\t\t334."},{"issue":"3","key":"i1551-6776-26-7-675-b200","series-title":"J Pharmacol Exp Ther","first-page":"1263","article-title":"Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception","volume":"274","year":"1995","unstructured":"Codd\n              EE,\n            \n            \n              Shank\n              RP,\n            \n            \n              Schupsky\n              JJ,\n            \n            \n              Raffa\n              RB.\n            \n          \n          Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception.\n\t\t\t\t\tJ Pharmacol Exp Ther.\n\t\t\t\t\t1995;\n\t\t\t\t\t274(\n\t\t\t\t\t3):\n\t\t\t\t\t1263\u2013\n\t\t\t\t\t1270."},{"issue":"2","key":"i1551-6776-26-7-675-b201","series-title":"J Pharmacol Exp Ther","first-page":"544","article-title":"Different effects of opioid antagonists on mu-, delta-, and kappa-opioid receptors with and without agonist pretreatment","volume":"321","year":"2007","unstructured":"Wang\n              D,\n            \n            \n              Sun\n              X,\n            \n            \n              Sadee\n              W.\n            \n          \n          Different effects of opioid antagonists on mu-, delta-, and kappa-opioid receptors with and without agonist pretreatment.\n\t\t\t\t\tJ Pharmacol Exp Ther.\n\t\t\t\t\t2007;\n\t\t\t\t\t321(\n\t\t\t\t\t2):\n\t\t\t\t\t544\u2013\n\t\t\t\t\t552."},{"issue":"10","key":"i1551-6776-26-7-675-b202","series-title":"Bioorg Med Chem Lett","first-page":"2811","article-title":"Design, synthesis, and characterization of 6beta-naltrexol analogs, and their selectivity for in vitro opioid receptor subtypes","volume":"19","year":"2009","unstructured":"Pelotte\n              AL,\n            \n            \n              Smith\n              RM,\n            \n            \n              Ayestas\n              M,\n            \n          \n          .\n\t\t\t\t\tDesign, synthesis, and characterization of 6beta-naltrexol analogs, and their selectivity for in vitro opioid receptor subtypes.\n\t\t\t\t\tBioorg Med Chem Lett.\n\t\t\t\t\t2009;\n\t\t\t\t\t19(\n\t\t\t\t\t10):\n\t\t\t\t\t2811\u2013\n\t\t\t\t\t2814."},{"issue":"2","key":"i1551-6776-26-7-675-b203","series-title":"J Pharmacol Exp Ther","first-page":"772","article-title":"Differential in vivo potencies of naltrexone and 6beta-naltrexol in the monkey","volume":"316","year":"2006","unstructured":"Ko\n              MC,\n            \n            \n              Divin\n              MF,\n            \n            \n              Lee\n              H,\n            \n          \n          .\n\t\t\t\t\tDifferential in vivo potencies of naltrexone and 6beta-naltrexol in the monkey.\n\t\t\t\t\tJ Pharmacol Exp Ther.\n\t\t\t\t\t2006;\n\t\t\t\t\t316(\n\t\t\t\t\t2):\n\t\t\t\t\t772\u2013\n\t\t\t\t\t779."}],"container-title":["The Journal of Pediatric Pharmacology and Therapeutics"],"original-title":[],"link":[{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/26\/7\/article-p675.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/meridian.allenpress.com\/jppt\/article-pdf\/26\/7\/675\/2909406\/i1551-6776-26-7-675.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/26\/7\/article-p675.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/26\/7\/article-p675.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:45:05Z","timestamp":1747356305000},"score":1,"resource":{"primary":{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/26\/7\/article-p675.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":203,"journal-issue":{"issue":"7"},"URL":"https:\/\/doi.org\/10.5863\/1551-6776-26.7.675","relation":{},"ISSN":["1551-6776"],"issn-type":[{"value":"1551-6776","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]}}}